7LWOSDJH 

6(3
&OLQLFDO6WXG\ 3URWRFRO6(3

$:HHN2SHQODEHO6DIHW\DQG7ROHUDELOLW\([WHQVLRQ6WXG\RI 
6(3LQ$GXOW6XEM HFWVZLWK6FKL]RSKUHQLD 
(XGUD&71R
&OLQWULDOVJRY,GHQWLILHU1&7

9HUVLRQ
2FWREHU
,QFRUSRUDWHV6XEVWDQWLDODPHQGPHQW
68129,213+$50$&(87,&$/6,1&
:DWHUIRUG'ULYH
0DUOERURXJK0$86$


Protocol SEP361-202, Version 34.00 SEP-363856 
 
Confidential and Proprietary 2  13 October 2017 RESTRICTED DISTRIBUT ION OF PROTOCOLS  
This document contains information confidential and/or of proprietary interest to Sumitomo 
Dainippon Pharma Co. Ltd. and/or Sunovion Pharmaceuticals Inc. (including their 
The information cannot be disclosed to any third party or predecessors,  subsidiaries or affiliates). 
used for any purpose other than the purpose for which it is being submitted without the prior 
written consent of the appropriate Sumitomo Dainippon Pharma company. 
This information is being provided to you for the purpose of conducting a clinical study for 
Sunovion Pharmaceuticals, Inc. You may disclose the contents of this protocol to the study 
personnel under your supervision and to your Institutional Review Board or Independent Ethics 
Committee for the above purpose. You may not disclose the contents of this protocol to any 
other parties, unless such disclosure is required by government regulations or laws, without the 
prior written permission of Sunovion Pharmaceuticals, Inc. 
Any data gathered during the conduct of this protocol and supplemental information (eg, a  
protocol amendment) that may be added to this document is also proprietary to Sunovion 
Pharmaceuticals, Inc, and should be handled consistently with that stated above. 
Protocol SEP361-202, Version 34.00 SEP-363856 
Confidential and Proprietary 3 13 October 2017 EMERGENCY CONTACTS  
Table 1: Emergency Contact Information 
Role in Study  Name Contact Information  
Responsi ble Physician   
Head of Global Clinical 
Development, Psychiatry 
Sunovion Pharmaceuticals Inc. Telephone: 
 Email: 
Medical Monitor   Medical Director Global 
Therapeutic 
QuintilesIMS Inc. Office: 
Mobile: 
Email:  
SAE/Pregnancy Reporting PPD Pharmacovigilance (PVG)  Hotline Number: 
 Fax: 
Email:  
Protocol SEP361-202, Version 34.00 SEP-363856 
Confidential and Proprietary 4 13 October 2017 1.SYNOPSIS
Name of Sponsor/Company: Sunovion Pharmaceuticals, Inc.  
Name of Investigational Product : SEP-363856 
Title of Study: A 26 -Week Open -label Safety and Tolerability Extension Study of SEP-363856 in 
Adult Subjects with Schizophrenia  
Proposed Indication : Schizo phrenia 
Study Centers:  Approximately 35 centers that have participated in Study SEP361-201  
Phase of Development: 2 
Study Objectives: 
Primary: The primary objective of this study is to evaluate the long -term safety and tolerability of 
flexibly dosed SEP -363856 (25, 50, or 75 mg/day [ie, once daily]) in adult subjects with schizophrenia 
who have completed Study SEP 361-201 by the incidence of overall adverse events (AEs), serious AE s 
(SAE s), and AEs leading to discontinuation.  
Secondary: 
‚Ä¢To evaluate the long- term safety and tolerability of SEP -363856 by assessing vital signs,
physical examinations (PE) , body weight and body mass index (BMI), 12- lead
electrocardiograms (ECG), clinical laboratory evaluations, and suicidal ideation and
suicidal behavior using the Columbia ‚Äì Suicide Severity Rating Scale (C -SSRS)
‚Ä¢To evaluate the long -term effectiveness of SEP -363856 using the Positive and Negative
Syndrome Scale (PANSS) total score, Clinical Global Impression -Severity (CGI -S),
PANSS subscale scores (positive, n egative, general psychopathology), Brief Negative
Systems Scale (BNSS), and Montgomery -Asberg Depression Rating Scale (MADRS)
‚Ä¢To explore the long -term maintenance of response in subjects treated with SEP -363856 as
measured by the time to relapse and the rate of relapse
Other:  
‚Ä¢To assess whether long -term treatment with SEP -363856 is associated with extrapyramidal
symptoms as measured by the Barnes Akathisia Rating Scale (BARS), the Abnormal
Involuntary Movement Scale (AIMS), and the Simpson -Angus Scale ( SAS)
‚Ä¢To characterize the long -term effects of SEP -363856 as measured by the Drug Effects
Questionnaire (DEQ)
‚Ä¢To characterize the subjective long -term effects of SEP -363856 on sleep as measured by
the Pittsburgh Sleep Quality Index (PSQI)
‚Ä¢To explore the effect s of SEP -363856 on cognition as assessed by the CogS tate Brief
Battery (CBB)  and the CogState Schizophrenia Battery (CSB)
‚Ä¢To explore the effects of SEP -363856 on func tional outcomes as measured by the UPSA -B
total score
Study Design:  
This is a 26 -week, mu ltiregional, open-label extension study designed to evaluate the long- term safety 
and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed 
Protocol SEP361-202, Version 34.00 SEP-363856 
Confidential and Proprietary 5 13 October 2017 the 4 -week double -blind treatment phase of Study SEP361-201. 
Subjects who m eet the entry criteria will transition immediately from Study SEP 361-201 (at Visit  7; 
assessments perf ormed at Study SEP361-201 Visit 7 will serve as the Baseline assessments for the 
present study). Informed consent will be obtained from all subjects befor e any study procedures are 
performed for the present study. 
Subjects will attend an initial visit on Day  1 (same day as Visit  7 of study SEP361-201). Subjects may 
be hospitalized for the first week of the present study, if deemed appropriate by the Investi gator. 
During the treatment period, clinic visits will occur as shown in the following figure, during which the 
procedures outlined in Table  2 will be conducted. Subjects will be seen at weekly intervals for the fir st 
4 weeks, then every 4  weeks thereafter up to week  26. Telephone calls will be made by a member of 
the clinical research staff to the subjects between scheduled study visits (between Weeks 1 and 2, and 
at Weeks 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25) to monitor clinical symptoms and adverse events. If subject appears to be symptomatic, an unscheduled visit will be made as early as possible.  Subjects 
who discontinue early from the study or complete study will be required to complete the follow-up visi t 
7 days (¬±  2 days) post last dose of study drug. 
Study Sc
hematic 
Note: Titration up to 7 5 mg/day is permitted (but not required) on Day 4 for reasons of efficacy as an unscheduled visit.
All 
subjects will receive open -label SEP-363856 50 mg/day from D ay 1 through Day 3. Beginning on 
Day 4, flexible dosing ranging from 25 to 75 mg/day is permitted, if deemed clinically necessary (for 
reasons of safety, tolerability, or efficacy) by the Investigator. On Day  4, subjects are permitted (but 
not required) to titrate up to 75  mg/day for reasons of efficacy . Thereafter, if a dose increase is 
necessary to optimize efficacy  it should occur at regular scheduled study visits based on Investigator 
judgement. Day  4 dosing changes will occur at an unscheduled visit. T hereafter, an increase in dose 
should occur at weekly intervals in increments of one dose level at a time to a maximum dose of 75 mg/day. Dose reduction for tolerability purposes is allowed  at any time during the study. 
Safety and tolerability will be monitored throughout the study by collection of physical examination 
results, ECGs, vital signs, AEs, clinical laboratory parameters, C -SSRS, body weight, and BMI. 
Subjects who have any new significant findings or worsening of findings for suicidal ideation or behavior upon completion of the C-SSRS at any time during the study must be referred to the 
investigator for follow -up evaluation. 
Subjects who meet any discontinuation/withdrawal criteria will be terminated from the study. Upon 
termination from the study, hospitalization will be allowed for up to 7 days to stabilize the subject, if 
necessary. Prior authorization for hospitalization must be approved by the Medical Monitor. 
Effectiveness will be evaluated using the PANSS total and subscale scores, as well as CGI -S, BNSS , 
and MADRS scores.  
Subjects will provide information on subjective drug effects via administration of the DEQ. In addition, effects on movement disorders will be measured using the AIMS, BARS and SAS scales. Subjective 
effects on sleep will b e measured by the PSQI scale.  Effects on cognition will be assessed by the 
Cogstate Brief  Battery (C BB) and the CogState Schizophrenia Battery (CSB), and a functional 

Protocol SEP361-202, Version 34.00 SEP-363856 
Confidential and Proprietary 6 13 October 2017 outcome measure (UPSA -B total score).  
Blood samples for determination of plasma SEP-363856 and SEP-363854 concentrations will be 
collected at Visit  2E, 5E, 8E, and 11E. Population pharmacokinetic (POPPK) analysis will be 
performed using plasma SEP-363856 concentrations; the results of which will be reported separately. 
Inclusion and Exclusion  Criteria: 
Inclusion Criteria:  
To qualify for participation, subjects must meet all of the following inclusion criteria:  
1.Subject must give written informed consent and privacy authorization prior to participation in
the study and able to comply with the protocol, in t he opinion of the investigator. Separate
consent will be obtained from a caregiver or legal guardian if required by local law.
2.Subject has completed Study SEP361-201 through Week 4.
3.Subject has n ot taken any medication other than the study drug for the purpose of controlling
schizophrenia symptoms during Study SEP361-201.
4.Female subject must have a negative urine pregnancy test at Visit  7 of Study SEP361-201;
females who are post -menopausal (defined as at least 12  months of spontaneous amenorrhea)
and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from
the pregnancy test.  Female subject of reproductive potential agrees to remain abstinent or use
highly effective  and reliable contraception throughout the study and for at least 30  days after
the last dose of study drug has been taken (See Section  21 Appendix II Highly Effective
Contraceptive procedures). In the Investigator's judgment, the subject will adhere to this
requirement.
5.Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a
child and use highly effective methods of birth control from screening until at least 30 days
after the last study drug administration.
Exclusion Crit eria: 
To qualify for participation, subjects must not meet any of the following exclusion criteria:  
1.Subject answers ‚Äúyes‚Äù to ‚Äúsuicidal ideation‚Äù Item  4 (active suicidal ideation with some intent
to act, without specific plan) or Item  5 (active suicidal ideation with specific plan and intent) 
on the C- SSRS assessment at Visit  7 of Study SEP 361-201. Subjects who answer ‚Äúyes‚Äù to this 
question must be referred to the Investigator for follow-up evaluation.  
2.Subject has a clinically significant abnormality includ ing physical examination, vital signs,
ECG, or laboratory test at Visit  7 of Study SEP 361-201 that the investigator in consultation 
with the medical monitor considers to be inappropriate to allow participation in the study . 
3.Subject has a positive urine drug screen (UDS) or breath alcohol test at Visit  7 of
Study SEP361-201. 
4.Subject is pregnant or lactating.
5.Subject is at high risk of non -compliance in the Investigator‚Äôs opinion.
6.Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this
study.
Investigational Product, Dosage and Mode of Administration: 
SEP-363856 treatment will be size 0, Swedish -orange capsules (25, 50, or 75 mg/day ) administered 
orally once daily . Study drug may be taken with or without food at appr oximately the same time each 
evening before bed- time.  
Protocol SEP361-202, Version 34.00 SEP-363856 
 
Confidential and Proprietary 7  13 October 2017 All subjects will be flexibly dosed with SEP -363856 at 25, 50, or 75  mg/day, provided as open -label 
patient packs.  
Duration of Treatment: 26 weeks 
Reference Therapy, Dosage and Mode of Administration:   
Not applicable.  
Concomitant Medications: 
Concomitant Non- psychotropic Medications : 
Medications for short- term treatment of an acute medical condition are allowed after consultation with 
the Medical Monitor. Non-psychotropic medications used to treat mil d, chronic medical conditions is 
allowed  if the dose and regimen have been stable (¬±  25%) for at least 30  days. The concomitant 
medication dose may change, as needed, after enrollment  (or be discontinued). Œí-adrenergic 
antagonists used to treat stable hypertension may be continued. In addition, use of non-prescription 
pain medications (eg, aspirin , acetaminophen) are allowed during all phases of the study provided these 
medications do not have a propensity for psychotropic effects and do not interfere with the evaluation 
of study medication. Female subjects may use oral, patch, or IUD hormonal contraceptives, or 
progestin implant or injection (detailed information on allowed contraceptives are defined in 
Section 21 , Appendix II ). 
Concomitant Psychotropic Medications : 
All antidepressants and mood stabilizers (eg, lithium, divalproex/valproic acid, carbamazepine, etc.) 
are not allowed during the study. 
Treatment with b enztropine (benzotropine outside the US) up to 6 mg/day will be permitted, as needed, 
for movement disorders. In cases where benztropine is not available or a subject has had an inadequate 
response or intolerability to benztropine treatment, the following medications may be used to treat 
acute extrapyramidal symptoms (EPS): biperiden (up to 16 mg/day) or trihexyphenidyl (up to 
15 mg/day) or diphenhydramine (up to 100 mg/day). Treatment with propranolol (up to 120 mg/day) 
will be per mitted as needed for akathisia.  
Medications used to treat movement disorders should not be given prophylactically. 
‚Ä¢ Concomitant use of lorazepam, temazepam, eszopiclone, zopiclone, zaleplon, zolpidem and 
zolpidem CR is permitted at the discretion of the Investigator with the follow ing restrictions: 
o Lorazepam (or equivalent benzodiazepine) is permitted for clinically significant 
anxiety/agitation or as a sedative/hypnotic up to a maximum daily dose of 6 mg/day. Intramuscular lorazepam is permitted up to 4  mg/day for acute anxiety/agi tation, as 
clinically indicated . Lorazepam should be used sparingly, when clinically required, per 
investigator judgment. 
o Temazepam (‚â§  30 mg/day), eszopiclone (‚â§ 3 mg/day), or zopiclone (‚â§ 7.5 mg/day), 
zaleplon (‚â§ 20mg/day), zolpidem (‚â§ 10  mg/day for males ; ‚â§ 5 mg/day for females), 
and zolpidem CR (‚â§ 12.5 mg/day for males; ‚â§ 6.25 mg/day for females) may be 
administered at b edtime for insomnia, as needed. 
o Hypnotic agents should be administered no more than once nightly and should not be used in combination.  
The date and time of the last dose taken prior to scheduled efficacy assessments must be recorded at each visit. Subjects should be encouraged to avoid taking these medications within 8 hours of scheduled efficacy assessments.  
Opioids may be allowed for a limited period of time with prior authorization from the Medical 
Monitor. 
In regions that do not have the specified drugs available, similar drugs at equivalent dosages will be 
Protocol SEP361-202, Version 34.00 SEP-363856 
 
Confidential and Proprietary 8  13 October 2017 permitted as described in the Operations Manual or in consult ation with the Med ical Monitor.  
Subjects should abstain from alcohol through the end of the study. 
Subjects who require treatment with one or more of the restricted concomitant medications (including 
other antipsychotics or anxiolytics [lorazepam or equivalent above protocol- specified limits]) will be 
discontinued (as appropriate) from the study. 
Criteria for Evaluation:  
Primary Endpoints:   
‚Ä¢ The incidence of overall AEs, SAEs, and AEs leading to discontinuation 
Secondary Endpoints:   
‚Ä¢ Absolute values and changes from double-blind (DB) Baseline of Study SEP 361-201 and 
open- label (OL) Baseline of Study SEP 361-202 in clinical laboratory tests (hematology, 
serum chemistry, urinalysis, glucose and lipid panel, prolactin, glycosylated hemoglobin 
(HbA 1c) 
‚Ä¢ Absolute values and changes from DB Baseline of Study SEP 361-201 and OL Baseline of 
Study SEP361-202 in clinical evaluations (vital signs body weight, BMI, blood pressure [supine and standing], heart rate [supine and standing], 12- lead ECGs)  
‚Ä¢ Frequency and severity of suicidal ideation and suicidal behavior using the C- SSRS 
‚Ä¢ Rate of relapse and time to relapse during the 26 -week OL period for subjects who 
demonstrated a clinical response to 4  weeks of treatment with SEP -363856. Relapse will 
be defined as the onset of any of the following: 
‚àí An increase in PANSS total score ‚â• 30% from the PANSS total score at clinical 
response and a CGI -S score ‚â• 3;  
‚àí Re-hospitalization for worsening of psychosis; 
‚àí Emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or 
others. 
‚Ä¢ Changes f rom DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 
in PANSS total score and subscale scores (positive, negative, and general psychopathology) 
‚Ä¢ Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in 
CGI-S score.  
‚Ä¢ Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in 
BNSS total score.  
‚Ä¢ Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in 
MADRS total score.  
‚Ä¢ Proportion of subjects who achieve a response, def ined as a 20% or greater improvement 
in PANSS total score from the baseline, and calculated using (1)  the DB Baseline of Study 
SEP361-201 for subjects assigned to double-blind SEP-363856, and (2) the OL Baseline of 
Study SEP361-202 for subjects assigned to double-blind placebo. 
Other Endpoints:  
‚Ä¢ Change from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in 
BARS, AIMS and SAS  scores.  
‚Ä¢ Absolute visual analogue scale (VAS) scores of the DEQ.  
Protocol SEP361-202, Version 34.00 SEP-363856 
 
Confidential and Proprietary 9  13 October 2017 ‚Ä¢ Change from DB Baseline of Study SEP361-201 and O L Baseline of Study SEP 361-202 in 
PSQI score.  
‚Ä¢ Change from DB  Baseline of Study SEP361-201 and OL Baseline of SEP361 -202 in CBB 
composite score  
‚Ä¢ Change from Week  12 of Study SEP361-202 in CSB composite score at Week 26 
‚Ä¢ Change from OL Baseline of Study SEP361-202 in UPSA- B total score  
Statistical Methods:  
The analysis of the long -term safety and tolerability, and efficacy will be based on the safety 
population, which includes all subjects who receive at least one dose of study drug during the 26- week 
OL exte nsion period.  
The primary analysis for the study is to assess the incidence of AEs, SAEs, and AEs leading to 
discontinuation. AEs, SAEs, and AEs leading to discontinuation will be summarized by the number and percentage of subjects with any AE, and AEs by system organ class and preferred term. AEs will 
be further summarized by severity and by relationship to study drug. The summary of AEs will be 
limited to those AE occurring on or after the first dose (of the 26 -week OL ex tension period) of study 
drug. 
Absolute values and changes from DB Baseline of Study SEP 361-201 and OL Baseline of Study 
SEP361-202 in clinical laboratory tests (hematology, serum chemistry, urinalysis, glucose and lipid 
panel, prolactin, glycosylated hemoglobin (HbA
1c)) and in clinical ev aluations (vital signs, body 
weight, BMI, blood pressure [supine and standing], heart rate [supine and standing], 12- lead ECGs) 
will be summarized descriptively. Changes in physical examinations will also be summarized 
descriptively. The frequency and severity of suicidal ideation and suicidal behavior using the C- SSRS 
will be provided . 
Clinical response to 4  weeks of treatment with SEP-363856 is defined as meeting both of the following 
criteria: (1) a decrease in PANSS total score of ‚â• 20% from baseline, and (2)  a CGI -S score ‚â§ 4. For 
subjects assigned to double-blind SEP-363856, clinical response will be evaluated using the Day 29 data of study SEP361-201, against the DB baseline of study SEP361-201. For subjects assigned to double-blind placebo, clinical response will be evaluated using the Day 29 data of study SEP361-202, 
against the OL baseline of study SEP 361-202. 
Relapse will be identified programmatically using the pre-defined criteria among subjects who demonstrated a clinical response to 4  weeks of treatment with SEP- 363856. The rate of relapse will be 
calculated as the proportion of subjects with a relapse in the 26 -week OL extension period, along with 
the 95% confidence interval. The time -to-relapse will be summarized descriptively and will also be 
presented by a Kaplan -Meier plot.  
Descriptive statistics will be presented  on the change in PANSS total and subscale scores, change in 
CGI-S score, change in BNSS total score, and change in MADRS  total score. Changes from DB 
Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 will be presented. The 
proportion of subjects who achieve a response, defined as a 20% or greater improvement in PANSS 
total score from the baseline, and calculated using (1) the DB Baseline of Study SEP361-201 for 
subjec ts assigned to double-blind SEP-363856,and (2) the OL Baseline of Study SEP361-202 for 
subjects assigned to double-blind placebo, will be calculated . 
Sample Size:  All subjects who complete the 4 -week double-blind treatment period of Study 
SEP361-201 are el igible  to enroll. It is anticipated that approximately 180 subjects will enter this 
open -label extension study.  
Protocol SEP361-202, Version 4.00 SEP-363856 
 
Confidential and Proprietary 10  13 October 2017 Table 2: Schedule of Assessments  
Study Visit Number  
Study Visit Week Visit 
1Ea 
Baseline Visit 
2E 
Week 1 Visit 
3E 
Week 2  
Visit 
4E 
Week 3 Visit 
5E 
Week 4 Visit 
6E 
Week 8 Visit 
7E 
Week 12 Visit 
8E 
Week 16 Visit 
9E 
Week 20 Visit 
10E 
Week 24 Visit 
11E 
Week 26 
or ETb Visit 12E 
Week 27 
Follow-upc 
EOS 
Study Visit Day  1 8 ¬± 2 15 ¬± 2 22 ¬± 2 29 ¬± 3 57 ¬± 3 85 ¬± 3 113 ¬± 3 141 ¬± 3 169 ¬± 3 183 ¬± 3 190 ¬± 2 
Obtain informed consent  X            
Review inclusion/exclusion 
criteria  X            
Dispense study drugd Xm X X X X X X X X X   
Study drug accountability   X X X X X X X X X X  
Telephone Contactse  Telephone call s to the  subjects will be made between Weeks  1 and 2 and at W eeks 5, 7, 9, 11, 13, 15, 17, 19, 21, 
23, and 25 . If subject appears to be symptomatic, an unscheduled visit will be made as early as possible.f  
Clinical and Laboratory Evaluations              
Adverse event (AE) monitoring  
Performed at Visit 7 
of study 
SEP361-
201 X X X X X X X X X X X 
Prior/concomitant medication 
review  X X X X X X X X X X X 
Physical and neurological examination     X X  X   X  
Vital signsg X  X X X X X X X X X 
Weight (including BMI)  X  X X X X X X X X  
Waist circumference  X  X X X X X X X X  
Electrocardiogram (ECG)  X   X X X X X X X  
Clinical laboratory testsh X   X   X   X  
Blood sample for POPPKi X   X   X   X  
Urine drug screenj X   X   X   X  
Urine Œ≤ -hCGk X X X X X X X X X X X 
Positive and Negative Syndrome Scale (PANSS)  X X X X X X X X X X  
Protocol SEP361-202, Version 4.00 SEP-363856 
 
Confidential and Proprietary 11  13 October 2017 Table 2: Schedule of Assessments  (Continued)  
Study Visit Number  
Study Visit Week Visit 
1Ea 
Baseline Visit 
2E 
Week 1 Visit 
3E 
Week 
2  
Visit 
4E 
Week 3 Visit 
5E 
Week 4 Visit 
6E 
Week 8 Visit 
7E 
Week 12 Visit 
8E 
Week 16 Visit 
9E 
Week 
20 Visit 
10E 
Week 24 Visit 
11E 
Week 26 
or ETb Visit 12E 
Week 27 
Follow-upc 
EOS 
Study Visit Day  1 8 ¬± 2 15 ¬± 2 22 ¬± 2 29 ¬± 3 57 ¬± 3 85 ¬± 3 113 ¬± 3 141 ¬± 3 169 ¬± 3 183 ¬± 3 190 ¬± 2 
Brief Negative Symptoms Scale 
(BNSS)  X X X X X X X X X X  
Clinical Global Impression ‚Äì 
Severity (CGI -S) X X X X X X X X X X  
Montgomery -Asberg Depression 
Rating Scale (MADRS)  X X X X X X X X X X  
Columbia Suicide Severity Rating Scale (C -SSRS)  X X X X X X X X X X X 
Drug effects questionnaire (DEQ)           X X 
Abnormal Involuntary 
Movement Scale (AIMS)l X X X X X X X X X X  
Barnes Akathisia Rating Scale 
(BARS)l X X X X X X X X X X  
Simpson-Angus Scale ( SAS)l X X X X X X X X X X  
Pittsburg Sleep Quality Index 
(PSQI) X   X  X   X X X 
Cogstate Cognition Battery 
(CBB)            
Cogstate Schizophrenia Battery (CSB)       X    X  
USPA -B X      X    X  
Abbreviations: AE = adverse event; AIMS  = Abnormal Involuntary Movement S cale; BARS  = Barnes Akathisia Rating Scale; Œ≤-hCG  = human chorionic gonadotropin; 
BNSS  = Brief Negative Symptoms Scale; CGI-S = Clinic al Global Impression ‚Äì Severity; CB B = Cogstate Brief Battery; CSB = CogState Schizophrenia Battery; 
C-SSRS = Columbia Suicide Severity Rating Scale ; ECG  = Electrocardiogram; ET = early termination; MADRS  = Asberg Depression Rating Scale; SAS  = Simpson- Angus 
Scale; PANSS  = Posit ive and Negative Syndrome Scale; PK = pharmacokinetic; PSQI  = Pittsburg Sleep Quality Index;  
a Results of assessments from Visit  7 (Week  4) of Study SEP 361-201 will serve as Baseline assessments for the present study. NOTE: Subjects may be hospitalized for the first 
week of the present study if deemed appropriate by the Investigator.  
Protocol SEP361-202, Version 4.00 SEP-363856 
 
Confidential and Proprietary 12  13 October 2017 b If a subject discontinues from the study, all Visit  11E procedures should be performed at the discontinuation visit, within 48 hours of last study dose.  
c All subjects will have a safety follow -up visit 7  (¬± 2) days after their last dose of study drug.  
d All study drug will be taken once daily in the eve ning by mouth.  
e Telephone calls will be made by a member of the research staff to the subjects between scheduled study visits (between Weeks  1 and 2, and at Weeks  5, 7, 9, 11, 13, 15, 17, 19, 
21, 23, and 25) to monitor clinical symptoms and adverse events. If subje ct appears to be symptomatic, an unscheduled visit will be made as early as possible.  
f Procedures and assessments for unscheduled visit are: drug accountability, physical and neurological examination, vital signs , ECG, clinical laboratory tests, urine dru g screen, 
PANSS, CGI -S, MADRS, BNSS, AIMS, BARS, SAS, and C -SSRS.  
g Vital signs will include supine and standing measurements of blood pressure and heart rate and respiratory rate and temperature.  
h Clinical laboratory tests include: hematology, serum chem istry, urinalysis, serum prolactin, glycosylated hemoglobin (HbA 1c), and glucose and lipid panel (subjects must be 
fasted [no food or drink except water at least 8  hours] prior to collection of blood samples for glucose and lipid panel).  
i Blood samples for determination of plasma SEP-363856 and SEP-363854 concentrations  will be collected at Visit  2E, 5 E, 8E, and 11E (time and date of the 3 previous doses of 
study medication and the time of the blood sampling must be recorded). Time of food intake relative to study drug taken should be recorded.  
j Urine drug screen may be ordered at other visits as deemed clinically appropriate. These results should be discussed with the  Medical Monitor.  
k Any positive urine Œ≤ -hCG test should be confirmed by a serum Œ≤ -hCG te st. 
l Unscheduled BARS, AIMS, and SAS scales should be administered if a subject develops extrapyramidal symptoms (EPS ) requiring treatment. See Section  10.3.  
m Titration up to 75  mg/day is permitted (but not required) on Day  4 for reasons of efficacy  as an unscheduled visit . At the minimum Investigator will assess AEs, concomitant 
medications and perform drug accountability at Day 4 unscheduled visit, all other assessments are not required but permitted based o n Investigators judgment.  
Note : With the exception of the  DEQ and the USPA -B, all rating assessments will be performed by the rater using a tablet. In the event that a tablet is not available, the rati ng 
assessments will be performed by the rater using a paper version of the assessment.  
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 13 13 October 2017 2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS  
RESTRICTED DISTRIBUT ION OF PROTOCOLS  ......................................................................2  
EMERGENCY CONTACTS ...........................................................................................................3  
1. SYNOPSIS  ...................................................................................................................4  
2. TABLE OF CONTENTS, L IST OF TABLES, AND LIST OF FIGURES  ...............13  
3. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS .............................19  
4. INTRODUCTION  ......................................................................................................23  
4.1. Background .................................................................................................................23  
4.2. Study Conduct Rationale ............................................................................................23  
4.3. Risk-Benefit Assessment  ............................................................................................25  
4.4. Hypothesis ..................................................................................................................25  
5. STUDY OBJECTIVES  ..............................................................................................26  
5.1. Primary Objective  .......................................................................................................26  
5.2. Secondary Objectives  .................................................................................................26  
5.3. Other Objectives  .........................................................................................................26  
6. STUDY ENDPOINTS  ................................................................................................27  
6.1. Primary Endpoints ......................................................................................................27  
6.2. Secondary Endpoints ..................................................................................................27  
6.3. Other Endpoints ..........................................................................................................28  
7. INVESTIGATIONAL PLAN  .....................................................................................29  
7.1. Overall Study Design  ..................................................................................................29  
7.2. Treatment Assignment and Blinding ..........................................................................30  
7.2.1.  Emergency Unblinding Procedures ............................................................................30  
7.3. Rationale  .....................................................................................................................30  
7.3.1.  Rationale for the Study Design  ...................................................................................30  
7.3.2.  Rationale for the Dosages ...........................................................................................30  
7.4. Prevention of Missing Data ........................................................................................31  
8. SELECTION OF SUBJECT S ....................................................................................32  
8.1. Subject Inclusion Criteria  ...........................................................................................32  
8.2. Subject Excl usion Criteria ..........................................................................................32  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 14 13 October 2017 9. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................34  
9.1. Description of Study Drug ..........................................................................................34  
9.2. Study Drug Packaging and Labeling  ..........................................................................34  
9.2.1.  Package Description  ...................................................................................................34  
9.2.2.  Labeling Descriptio n ..................................................................................................34  
9.3. Study Drug Storage  .....................................................................................................35  
9.4. Dispensing of Study Drug ..........................................................................................35  
9.5. Study Drug Accountability .........................................................................................35  
9.6. Study Drug Handling and Disposal ............................................................................35  
10. TREATMENT OF SUBJECTS ..................................................................................36  
10.1.  Study Drug  ..................................................................................................................36  
10.1.1.  Dosage Adjustment Criteria  .......................................................................................36  
10.2.  Treatment Compliance  ................................................................................................36  
10.3.  Concomitant Medications and Restrictions ................................................................36  
10.3.1.  Concomitant Nonpsychotropic Medications ..............................................................37  
10.3.2.  Concomitant Psychotropic Medications .....................................................................37  
10.3.3.  Prohibited Medications ...............................................................................................38  
10.3.4.  Prohibited Therapies ...................................................................................................38  
10.4.  Other Restrictions  .......................................................................................................39  
10.5.  Description of Study Periods and Hospital Discharge ...............................................39  
10.5.1.  Description of Study Periods ......................................................................................39  
10.5.2.  Hospital Discharge During the Study .........................................................................39  
10.6.  Guidance for Overdose ...............................................................................................40  
11. STUDY ASSESSMENTS  ..........................................................................................41  
11.1.  Demographics and Baseline Characteristics  ...............................................................41  
11.2.  Prior and Concomitant Medication Review ...............................................................41  
11.3.  Efficacy Assessments  .................................................................................................41  
11.3.1.  Positive and Negative Syndrome Scale (PANSS)  ......................................................41  
11.3.2.  Brief Negative Symptom Scale (BNSS)  .....................................................................41  
11.3.3.  Montgomery- Asbe rg Depression Rating Scale (MADRS)  ........................................42  
11.3.4.  Clinical Global Impressions ‚Äì Severity Scale (CGI -S) ..............................................42  
11.3.5.  CogState Brief Battery (CBB) and CogState Schizophrenia Battery (CSB)  ..............42  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 15 13 October 2017 11.3.6.  University of California, San Diego, Performance- Based Skills Assessment -
Brief (USPA -B) ..........................................................................................................43  
11.4.  Safety Assessments  .....................................................................................................43  
11.4.1.  Adverse Events  ...........................................................................................................43  
11.4.2.  Clinical Laboratory Tests  ...........................................................................................43  
11.4.3.  Vital Signs  ..................................................................................................................43  
11.4.4.  Electrocardiograms (ECGs)  ........................................................................................44  
11.4.5.  Physica l and Neurological Examination  .....................................................................44  
11.4.6.  Height, Weight, and BMI ...........................................................................................44  
11.4.7.  Safety Scales  ...............................................................................................................45  
11.4.7.1.  Abnormal Involuntary Movement Scale (AIMS) .......................................................45  
11.4.7.2.  Barnes Akathisia Rating Scale (BARS)  .....................................................................45  
11.4.7.3.  Simpson- Angus Scale (SAS)  ......................................................................................45  
11.4.7.4.  Columbia Suicide Severity Rating Scale (C -SSRS)  ...................................................45  
11.4.7.5.  Drug Effec ts Questionnaire (DEQ) ............................................................................45  
11.4.7.6.  Pittsburg Sleep Quality Index (PSQI).........................................................................46  
11.5.  Population Pharmacokinetic Assessments ..................................................................46  
11.6.  Study Visits and Assessments  ....................................................................................46  
11.6.1.  Baseline: Visit 1E (Day  1) ..........................................................................................46  
11.6.2.  Visit 2E (Week  1; Day  8 ¬± 2) .....................................................................................48  
11.6.3.  Visit 3E (Week  2; Day  15 ¬± 2) ...................................................................................48  
11.6.4.  Visit 4E (Week  3; Day  22 ¬± 2) ...................................................................................49  
11.6.5.  Visit 5E (Week  4; Day  29 ¬± 3) ...................................................................................49  
11.6.6.  Visit 6E (Week  8; Day  57 ¬± 3) and Visit 7E (Week  12; Day 85 ¬± 3)  ........................50  
11.6.7.  Visit 8E (Week  16; Day 113 ¬± 3) ...............................................................................51  
11.6.8.  Visit 9E (Week  20; Day 141 ¬± 3) and Visit 10E (Week  24; Day 169 ¬± 3) ................52  
11.6.9.  Visit 11E (Week  26; Day 183 ¬± 3, Early Termination) ..............................................53  
11.6.10.  Visit 12E (Week  27; Day 190 ¬± 2, Follow-up, End of Study) ...................................53  
11.6.11.  Unscheduled Visit (Subjects Who Appear Symptomatic during Telephone 
Contacts)  .....................................................................................................................54  
12. SAFETY REPORTING  ..............................................................................................55  
12.1.  Definitions  ..................................................................................................................55  
12.1.1.  Adverse Events  ...........................................................................................................55  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 16 13 October 2017 12.1.2.  Serious Adverse Events  ..............................................................................................55  
12.2.  Objective Findings  ......................................................................................................56  
12.3.  Collection and Recording of Adverse Events .............................................................56  
12.4.  Immediately Reportable Events  ..................................................................................58  
12.4.1.  Serious Adverse Event ................................................................................................58  
12.4.2.  Pregnancy  ...................................................................................................................59  
13. TERMINATION OF SUBJECT FROM STUDY/DISCONTINUATION OF 
STUDY DRUG  ...........................................................................................................60  
13.1.  Criteria for Subject Termination/ Study Drug Discontinuation ..................................60  
13.2.  Clinical Assessments after Study Drug Discontinuation  ............................................60  
14. STUDY TERMINATION ..........................................................................................61  
15. STATISTICS  ..............................................................................................................62  
15.1.  Sample Size  ................................................................................................................62  
15.2.  Analysis Population ....................................................................................................62  
15.2.1.  Safety Population ........................................................................................................62  
15.3.  Data Analysis  ..............................................................................................................62  
15.3.1.  Subject Disposition  .....................................................................................................62  
15.3.2.  Drug Exposure and Compliance .................................................................................62  
15.3.3.  Important Protocol Deviations ....................................................................................63  
15.3.4.  Demographic and Baseline Characteristics  ................................................................63  
15.3.5.  Efficacy Analyses  .......................................................................................................63  
15.3.6.  Safety Analyses  ..........................................................................................................64  
15.3.6.1.  Adverse Events  ...........................................................................................................64  
15.3.6.2.  Clinical Laboratory Assessments  ...............................................................................65  
15.3.6.3.  ECGs  ...........................................................................................................................65  
15.3.6.4.  Vital Signs  ..................................................................................................................65  
15.3.6.5.  Physical/Neurological Examination  ...........................................................................65  
15.3.6.6.  Concomitant Medications ...........................................................................................65  
15.3.6.7.  Suicidality Measure  ....................................................................................................66  
15.3.6.8.  Rate of Relapse and Time to Relapse  .........................................................................66  
15.3.6.9.  Movement Disorder Measures ....................................................................................66  
15.3.6.10.  Drug Effects Questionnaire  ........................................................................................66  
15.3.6.11.  Pittsburgh Sleep Quality Index ...................................................................................66  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 17 13 October 2017 15.3.6.12.  Subgroup Analysis ......................................................................................................67  
15.3.7.  Pharmacokinetic Analysis  ..........................................................................................67  
15.3.8.  Pharmacodynamic Analysis ........................................................................................67  
15.3.9.  Interim Analysis  ..........................................................................................................67  
15.3.10.  Treatment of Missing Data  .........................................................................................67  
15.3.11.  Sensitivity Analyses  ....................................................................................................67  
16. PROCEDURE FOR CLINICAL STUDY QUALITY CONTROL /DATA 
COLLECT ION, MANAGEMENT, AND QUALITY ASSURANCE  ......................68  
16.1.  Data Collection/Electronic Data Capture (EDC)  ........................................................68  
16.2.  Computerized Systems Used  for Source Data  ............................................................68  
16.3.  Study Monitoring ........................................................................................................69  
16.4.  Audits ..........................................................................................................................69  
16.5.  Study Documentation  .................................................................................................70  
16.6.  Clinical Laboratory Certification and Normal Values  ................................................70  
17. ETHICAL AND REGULATORY OBLIGATIONS ..................................................71  
17.1.  Study Conduct ............................................................................................................71  
17.2.  Institutional Review Board/Independent Ethics Committee  ......................................71  
17.3.  Informed Consent .......................................................................................................71  
17.4.  Subject Privacy  ...........................................................................................................72  
17.5.  Protocol Amendments and Emergency Deviations ....................................................72  
17.6.  Records Retention  .......................................................................................................73  
17.7.  Inspection of Records .................................................................................................73  
17.8.  Publication Policy  .......................................................................................................73  
18. REFERENCES  ...........................................................................................................74  
19. INVESTIGATOR APPROVA L .................................................................................77  
20. APPENDIX I. CARDIAC  SAFETY  MONITORING (ECG)  ....................................78  
21. APPENDIX II . HIGHLY EFFECTIVE C ONTRACEPTIVE  
PROCEDURES  FOR  AND D URING T HE STUDY ................................................79  
22. APPENDIX III.  CLINICAL  LABORATORY T ESTS  ..............................................80  
23. APPENDIX IV. PHARMACOKINETIC  SAMPLING  AND S AMPLE  
HANDLING G UIDELINE  .........................................................................................81  
 
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 18 13 October 2017  
 
 
LIST OF TABLES  
Table 1:  Emergency Contact Information ...................................................................................3  
Table 2:  Schedule of Assessments  ............................................................................................10  
Table 3:  List of Abbreviations ..................................................................................................19  
Table 4:  Definition of Key Study Terms  ..................................................................................22  
Table 5:  Investigational Product ...............................................................................................34  
Table 6:  Concomitant M edications/Therapies: Use During Study  ...........................................37  
Table 7:  Description of Study Periods ......................................................................................39  
 
LIST OF FIGURES  
Figure  1 Study Schematic  .........................................................................................................29  
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 19 13 October 2017 3. LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS 
The abbreviations and the definition of key study terms used in the clinic al study protocol are 
shown in Table 3 and  Table  4. 
Table 3: List of Abbreviations 
Abbreviation  Full Form  
AE Adverse event  
AIMS  Abnormal Involuntary Movement Scale  
ALT  Alanine aminotransferase  
ANCOVA Analysis of covariance  
AST  Aspartate aminotransferase  
ATC  Anatomical Therapeutic Chemical  
BARS  Barnes Akathisia Rating Scale  
BMI  Body mass index  
BNSS  Brief Negative Symptom Scale  
BOLD  Blood oxyge n level dependent  
BUN  Blood urea nitrogen 
CDR  Clinical data repository  
CFR Code of Federal Regulations 
CGI-I Clinical global impression - improvement 
CGI-S Clinical global impression - severity  
CIMS  Clinical Inventory Management System  
CLIA  Clinical Laboratory Improvement Amendments 
CNS  Central nervous system  
CRF  Case report form  
CRO  Contract research organization  
CS Clinically significant  
C-SSRS  Columbia ‚Äì Suicide Severity Rating Scale  
CYP  cytochrome 
DEQ Drug Effects Questionnaire 
ECG  Electr ocardiogram  
EDC  Electronic data capture  
EEG  Electroencephalogram 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 20 13 October 2017 Table 3: List of Abbreviations (Continued)  
Abbreviation  Full Form  
ET Early termination  
FDA U.S. Food and Drug Administration 
fMRI  functional magnetic resonance imaging (fMRI)  
GCP  Good Clinical Practice  
5-HT 5-hydroxytryptamine (serotonin) 
HIV Human immunodeficiency virus  
ICH International Conference on Harmonization 
IEC Independent Ethics Committee  
IND Investigational New Drug  
IPD Important protocol devi ation  
IRB Institutional Review Board  
IXRS  Interactive voice/web response system  
LOCF Last Observation Carried Forward  
LIMS  Laboratory information management system  
MADRS  Montgomery- Asberg Depression Rating Scale  
MedDRA  Medical Dictionary for Regulatory Activities  
MID  Monetary incentive delay  
mITT Modified Intention- to-Treat 
MMRM  Mixed -effects Models Repeated Measures  
MoA Mechanism of action  
SAS Simpson- Angus Scale  
MTD  Maximum tolerated dose 
N2 NREM sleep stage 2  
N3 NREM sleep stage 3  
NCS  Not clinically significant  
NREM  Non-rapid eye movement sleep  
PANSS Positive and negative syndrome scale  
PD Pharmacodynamic(s)  
PE Physical examination  
PGx Pharmacogenomic(s)  
PK Pharmacokinetic(s)  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 21 13 October 2017 Table 3: List of Abbreviations (C ontinued)  
Abbreviation  Full Form  
POPPK  Population pharmacokinetics 
PR Time between P wave and QRS in electrocardiography  
PSG polysomnography 
PSQI  Pittsburgh Sleep Quality Index  
PT Preferred term  
QD Once daily 
QRS  Electrocardiographic wave (complex o r interval)  
QT Electrocardiographic interval from the beginning of the QRS 
complex to the end of the T wave 
QTc QT interval corrected for heart rate  
REM  Rapid eye movement 
RR Respiration rate  
SAD single ascending dose 
SAE  Serious adverse event  
SCID -CT Structured Clinical Interview for DSM -IV, Clinical Trials Version  
SOC  System organ class  
TAAR1  trace amine associated 1 receptors  
US, USA United States, United States of America  
USP United States Pharmacopeia 
VAS  Visual analogue scale  
WBC White bl ood cells  
WHO World Health Organization 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 22 13 October 2017 Table 4: Definition of Key Study Terms  
Terms Definition of terms  
CRF  A printed, optical, or electronic document designed to record all 
of the protocol required information to report to the Sponsor for 
each study subject. 
Screened Subject  Any subject who signed the study specific informed consent and completed at least one study related procedure. 
Screen Failures  Any subject who signed the study specific informed consent but either failed to meet study requirements during baseline or met 
study requirements at baseline but was not enrolled. 
Study Drug (or 
Investigational 
Product) Term to cover investigational drug.  
Treatment P eriod  The period of the study in which the study drug is administ ered.  
Enrolled Subject Any subject who was successfully screened and was dispensed 
study drug. 
Completed Subject Any subject who participated throughout the duration of the study, up to and including the last follow-up visit.  
Early Termination Subject  Any subject who was successfully screened and entered  into the 
treatment period of the study, but did not complete the study. 
End of Treatment  The day that the subject receives protocol-defined last dose of the 
study drug. This may or may not include a taper period.  
End of Study The day that the subject completes the study per the study design. 
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 23 13 October 2017 4. INTRODUCTION 
4.1. Background  
Schizophrenia is a chronic and disabling neurodegenerative disorder characterized by a mixture 
of positive symptoms (eg, hallucinations, delusions, and thought and movement disorders), negative symptoms (eg, flat affect, anhedonia, alogia, and avolition), and cognitive deficits (eg, 
impaired memory, attention, and planning/organizing). Mood symptoms such as depression, 
anxiety, hostility, a nd excitement can also be present in patients with schizophrenia ( Patel -2007; 
NIMH -2010). Despite scientific advances, schizophrenia remains one of the most challenging 
diseases to treat due to its variable nature, the heterogeneity of clinical response, the side effects of treatment, and its association with high morbidity and mortality ( Lehman -2004; Tandon-2008; 
NIMH -2010). 
Schizophrenia has an estimated population prevalence of approximately 1% (estimated 2.4 million adults), with a diagnosed prevalence of 0.51% in the United States ( Narrow -2002; 
Wu-2006). It affects both genders equally (NIMH -2010) typically first manifesting in young 
adults, with the peak ages of onset in the early to mid 20s in men and late 20s in women (APA-2000). It is believed to be caused by a combination of genetic and environmental factors 
(Minzenberg-2008). Dopaminergic, serotonergic and glutamatergic systems are believed to play 
a role in schizophrenia ( Kuroki-2008; Kim-2009).  
The current standard of care for the treatment of schizophrenia is the use of second generation antipsychotics or ‚Äúatypical antipsychotics‚Äù (Lehman 2004; Kreyenbuhl-2009; NIMH -2010; 
Meltzer -2011; Nakamura -2009). These ‚Äúatypicals‚Äù are thought to have fewer extrapyramidal 
side effects compared to first generation antipsychotics or ‚Äútypical antipsychotics‚Äù (eg, haloperidol) ( Leucht-2009; Naber -2009 ). However some patients respond poorly to both atypical 
and typical antipsychotics and some continue to have symptoms and substantial functional/cognitive impairment ( Keefe -2006; Webber -2008 ). Very few patients return to 
Baseline (pre psychosis) function ( Schultz-1999;  Pearlson -2000; Kapur-2001). In addition, some 
atypical agents have a variety of other side effects, including weight gain, metabolic syndrome, sedation , QTc prolongation, extrapyramidal symptoms and tardive dyskinesia ( Davis -2004; 
Lieberman -2005; Newcomer -2007; Leucht 2009), which may lead to significant medical 
problems as well as contribute to poor compliance and treatment discontinuation. The large sc ale 
NIMH -CATIE schizophrenia study found that 70% to 80% of outpatients discontinue 
medications because of lack of efficacy or occurrence of side effects (Lieberman 2005) often 
leading to relapse of symptoms and need for rehospitalization ( Ascher -Svanum-2010; 
Munro-2011; Morken-2008). Clearly, an unmet need exists for new, effective, and well- tolerated 
treatments . 
4.2. Study Conduct Rationale  
SEP-363856 is a CNS-active compound, which shows broad efficacy in animal models of 
schizophrenia (positive and negative symptoms), cognition and depression. The molecular target 
responsible for the profile effects has not been completely elucidated, but may include actions at 
5 HT1A and trace amine associated 1 (TAAR1) receptors. Rat electroencephalogram (EEG) 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 24 13 October 2017 studies showed that SEP-363856 suppressed rapid eye movement (REM) sleep in a dose 
dependent manner. In nonhuman primate functional magnetic resonance imaging (fMRI) 
experiments, similar to risperidone, pretreatment with SEP -363856 also reduced the ketamine 
brain fMRI response in rhesus monkey supporting an antipsychotic- like profile. Taken together, 
these data demonstrate that SEP -363856 exhibits clear, functional CNS PD signals in rats and 
nonhuman primates. 
To date, 210 subjects have received oral doses of SEP -363856 in six Phase 1 clinical studies. 
Five Phase 1 studies have been completed (SEP361-101, SEP361-103, SEP361-105, 
SEP361-106, and SEP361-108). One Phase 1 study has been clinically completed (SEP361-104). 
The first in human clinical study, a single ascending dose study (SAD; Study SEP361-101), was designed to determine the safety, tolerability, maximum tolerated dose (MTD), and PK of a 
single oral dose of SEP-363856 in normal , healthy, adult male subjects.  
Study SEP361-103 was a randomized, double-blind, plac ebo-controlled, crossover 
polysomnography (PSG) study that investigated the e ffect of a single oral dose (50  mg and 
10 mg) of SEP -363856 on REM sleep suppression and PK in healthy adult male subjects. A 
single 50 mg oral dose of SEP-363856 suppressed REM s leep in all subjects (increased latency 
to REM sleep and reduced time spent in REM sleep) and increased NREM sleep stage 2 (N2), and NREM sleep stage 3 (N3) (deep or slow wave sleep). A single oral 10 mg dose of 
SEP-363856 also increased latency to REM sleep to a lesser extent, but did not reduce time spent 
in REM sleep. Taken together, results from these 2 studies in healthy adult male subjects 
demonstrated acceptable safety profile as well as robust CNS effect.  
Study SEP361-105 was a randomized, single-blind, placebo-controlled, SAD study assessing the 
safety, tolerability, and PK of SEP-363856 in male and female subjects with schizophrenia. 
Study SEP361-106 was a 2 part, randomized, single-blind, placebo-controlled, multiple 
ascending oral dose (MAD) and open- label study in male and female schizophrenic patients 
assessing the safety, tolerability, and PK of SEP-363856 in the target patient population. Results 
from this study demonstrate an acceptable safety and tolerability profile of SEP -363856 up to 
28 days in schizophrenia patients. Additionally, in Part 2, treatment with SEP -363856 at 
75 mg/day for 28  days demonstrated improvement in efficacy m easures (PANSS total score, 
CGI-S) compared with Baseline. Furthermore, ad hoc subgroup analyses showed a signi ficantly 
greater decrease from Baseline in PANSS total scores at the end of the 28 -day treatment period 
in subjects who had less frequent hospitalizations per year of illness compared with subjects who had more frequent hospitalizations per year of illness. 
Study SEP361-104 was a randomized, double-blind, placebo-controlled, single dose study of the 
effects of SEP -363856 (50 mg) and amisulpride (400 mg) on BOLD- fMRI signal in healthy adult 
male and female subjects with high or low schizotype characteristics . Subjects with high 
schizotype characteristics and patients with schizophrenia share many similar features including positive, cognitive, negative and anhedonia symptoms, although in high schizotypes the features 
present in an attenuated form. In this study, fMRI was used in combination with a validated 
monetary incentive delay (MID) task to examine the single dose effects SEP -363856 on changes 
in reward processing. During the anticipation/motivational phase of the task, SEP-363856 
modulated striatum, insu la and orbitofrontal cortex brain activity, and fMRI effects of 
SEP-363856 were similar to those observed with the D2 antagonist amisulpride. During the 
outcome/hedonic phase of the task, SEP-363856 generally increased brain activity in core reward 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 25 13 October 2017 areas ( striatum, insula), whereas amisulpride decreased brain activity in these same regions. 
Taken together the overall pattern of activity during MID task performance support specific 
hypotheses for the potential of SEP-363856, a novel MoA molecule, to improve positive and 
negative symptoms of schizophrenia. Overall, the known molecular pharmacology profile, animal model evidence, and clinical experience in healthy adult male and female subjects, adult 
male and female subjects with high and low schizotype characteristics, and patients with 
schizophrenia provide further support to evaluate SEP-363856 as a potential treatment for schizophrenia. 
This is an open-label extension study to further evaluate the safety and tolerability of 
flexibly -dosed SEP -363856 (25, 50 or 75 mg) over 26 weeks of treatment in adult subjects with 
schizophrenia who completed 4 weeks of double- blind treatment Study SEP 361-201. 
4.3. Risk-Benefit Assessme nt 
Overall, in previous clinical studies SEP -363856 was generally safe and well tolerated. The 
pharmacokinetic (PK) and safety profiles observed in adults from completed clinical studies support evaluation of dose levels of 25 to  75 mg /day in adults with schizophrenia. 
Schizophrenia is a life -long disorder and despite advances in drug treatment man y patients 
continue to experience symptoms with impaired quality of life. SEP -363856 has a unique 
mechanism of action and, if successful, could provide a major step forward in the treatment of 
schizophrenia. Moreover, its unique mechanism of action suggest that it has fewer side effects 
than traditional antipsychotics and, therefore, is likely to be well tolerated by subjects in this study.  
4.4. Hypothesis  
This is an open-label extension study to evaluate long- term safety and tolerability of 
SEP-363856. No stati stical hypothesis tests will be performed.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 26 13 October 2017 5. STUDY OBJECTIVES  
5.1. Primary Objective  
The primary objective of this study is to evaluate the long- term safety and tolerability of flexibly 
dosed SEP -363856 (25, 50, or 75 mg/day  [ie, once daily]) in adult subjects with schizophrenia 
who have completed Study SEP361- 201 by the incidence of overall adverse events (AEs ), 
serious AEs (SAE s), and AEs leading to discontinuation. 
5.2. Secondary Objectives  
‚Ä¢ To evaluate the long -term safety and tolerability of SEP-363856 by assessing vital 
signs, physical examinations  (PE), body weight and body mass index (BMI), 12- lead 
electrocardiograms (ECG), clinical laboratory evaluations, and suicidal ideation and 
suicidal behavior using the Columbia - Suicide Severity Rating Scale (C -SSRS)  
‚Ä¢ To evaluate the long -term effectiveness of SEP-363856 using the Positive and 
Negative Syndrome Scale (PANSS) total score, Clinical Global Impression -Severity 
(CGI -S), PANSS subscale scores (positive, negative, general psychopathology), Brief 
Negative Systems S cale (BNSS), and Montgomery- Asberg Depression Rating Scale 
(MADRS)  
‚Ä¢ To explore the long- term maintenance of response in subjects treated with 
SEP-363856 as measured by the time to relapse and the rate of relapse  
5.3. Other Objectives  
‚Ä¢ To assess whether long- term treatment with SEP-363856 is associated with 
extrapyramidal symptoms as measured by the Barnes Akathisia Rating Scale (BARS), the Abnormal Involuntary Movement Scale (AIMS), and the Simpson-Angus Scale ( SAS) 
‚Ä¢ To characterize the long -term effects of SEP-363856 as measured by the Drug Effects 
Questionnaire (DEQ) 
‚Ä¢ To characterize the subjective long -term effects of SEP-363856 on sleep as measured 
by the Pittsburgh Sleep Quality Index (PSQI) 
‚Ä¢ To explore the effects of SEP -363856 on cognition as assessed by the Co gState Brief 
Battery (CBB) and the CogState Schizophrenia Battery (CSB)  
‚Ä¢ To explore the effects of SEP-363856 on functional outcomes as measured by  the 
UPSA -B total score  
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 27 13 October 2017 6. STUDY ENDPOINTS  
6.1. Primary Endpoint s 
‚Ä¢ The incidence of overall AEs, SAEs, and AEs leading to discontinuation 
6.2. Secondary Endpoints  
‚Ä¢ Absolute values and changes from double-blind (DB) Baseline of Study SEP361-201 
and open- label (OL) Baseline of Study SEP 361-202 in clinical laboratory tests 
(hematology, serum chemistry, urinalysis, glucose and lipid panel, prolactin, 
glycosylated hemoglobin (HbA 1c)) 
‚Ä¢ Absolute values and changes from DB Baseline of Study SEP361-201 and OL 
Baseline of Study SEP 361-202 in clinical evaluations (vital signs body weight, BMI, 
blood pressure [supine and standing], heart rate [supine and standing], 12- lead ECGs)  
‚Ä¢ Frequency and severity of suicidal ideation and suicidal behavior using the C- SSRS  
‚Ä¢ Rate of relapse and time to relapse during the 26 -week OL period for subjects who 
demonstrated a clinical response to 4  weeks of treat ment with SEP-363856. Relapse 
will be defined as the onset of any of the following: 
‚àí An increase in PANSS total score ‚â• 30% from the PANSS total score at clinical 
response and a CGI- S score ‚â• 3 
‚àí Re-hospitalization for worsening of psychosis 
‚àí Emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or 
others. 
‚Ä¢ Changes from DB Baseline of Study SEP361-201 and OL Baseline of Study SEP361-202 in PANSS total score and subscale scores (positive, negative, and 
general psychopathology) 
‚Ä¢ Change from DB Baseline of Study SEP 361-201 and OL Baseline of 
Study SEP 361-202 in CGI- S score.  
‚Ä¢ Change from DB Baseline of Study  SEP 361-201 and OL Baseline of 
Study SEP 361-202 in BNSS total score. 
‚Ä¢ Change from DB Baseline of Study SEP 361-201 and OL Baseline of 
Study SEP36 1-202 in MADRS total score. 
‚Ä¢ Proportion of subjects who achieve a response, defined as a 20% or greater improvement in PANSS total score from the baseline, and calculated using (1)  the DB 
Baseline of Study SEP 361-201 for subjects assigned to double-blind SEP -363856, 
and (2) the OL Baseline of Study SEP 361-202 for subjects assigned to double-blind 
placebo . 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 28 13 October 2017 6.3. Other Endpoi nts 
‚Ä¢ Change from DB Baseline of Study SEP 361-201 and OL Baseline of Study 
SEP361-202 in BARS, AIMS and SAS  scores.  
‚Ä¢ Absolute visual analogue scale (VAS) scores of the DEQ.  
‚Ä¢ Change from DB Baseline of Study SEP 361-201 and OL Baseline of 
Study SEP 361-202 in PSQ I score.  
‚Ä¢ Change from DB Baseline of Study SEP 361-201 and OL Baseline of 
Study SEP 361-202 in CBB composite score. 
‚Ä¢ Change from Week  12 of Study SEP361-202 in CSB composite score at Week 26 
‚Ä¢ Change from OL Baseline of Study SEP361-202 in UPSA- B total score . 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 29 13 October 2017 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a 26-week, multiregional, open- label extension study designed to evaluate the long -term 
safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have 
completed the 4 -week dou ble-blind treatment phase of Study SEP361-201. 
Subjects who meet the entry criteria will transition immediately from Study SEP 361-201 (at 
Visit 7; assessments performed at Study SEP 361-201 Visit 7 will serve as the Baseline 
assessments for the present stud y). Informed consent will be obtained from all subjects before 
any study procedures are performed for the present study.  
Subjects will attend an initial visit on Day  1 (same day as Visit  7 of study SEP361-201). Subjects 
may be hospitalized for the first we ek of the present study, if deemed appropriate by the 
Investigator. During the treatment period, clinic visits will occur as shown in the following 
figure, during which the procedures outlined in Table 2 will be con ducted. Subjects will be seen 
at weekly intervals for the first 4  weeks, then every 4  weeks thereafter up to week 26. Telephone 
calls will be made by a member of the clinical research staff to the subjects between scheduled study visits (between Weeks 1 an d 2, and at Weeks 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25) to 
monitor clinical symptoms and adverse events. If subject appears to be symptomatic, an 
unscheduled visit will be made as early as possible. Subjects who discontinue early from the 
study or complete study will be required to complete the follow-up visit 7 days (¬±  2 days ) post 
last dose of study drug. 
 
Figure 1 Study Schematic  
 
Note: Titration up to 7 5 mg/day is permitted (but not required) on Day 4 for reasons of efficacy as an unscheduled visit.  
 
All subjects will receive open -label SEP-363856 50 mg/day from Day  1 through Day 3. 
Beginning on Day 4, flexible dosing ranging from 25 to 75 mg/day is permitted, if deemed 
clinically necessary (for reasons of safety, tolerability, or efficacy) by the Investigator. On Day  4, 
subjects are permitted (but not required) to titrate up to 75  mg/day  for reasons of efficacy . 
Thereafter, if a dose increase is necessary to optimize efficacy it should occur at regular scheduled study visit based on Investigator judgement. Day 4 dosing changes will occur at an 
unscheduled visit. Thereafter, an increase in dose should occur at weekly intervals in increments of one dose level at a time to a maximum dose of 75 mg/day. Dose redu ction for tolerability 
purposes is allowed at any time during the study.  

Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 30 13 October 2017 Safety and tolerability will be monitored throughout the study by collection of physical 
examination results, ECGs, vital signs, AEs, clinical laboratory parameters, C -SSRS, body 
weig ht, and BMI. Subjects who have any new significant findings or worsening of findings for 
suicidal ideation or behavior upon completion of the C- SSRS at any time during the study must 
be referred to the investi gator for follow -up evaluation. 
Effectiveness will be evaluated using the PANSS total and subscale scores, as well as CGI -S, 
BNS S, and MADRS scores. 
Subjects will provide information on subjective drug effects via administration of the DEQ. In 
addition, effects on movement disorders will be measured using the AIMS, BARS and SAS  
scales. Subjective effects on sleep will be measured by the PSQI scale. Effects on cog nition will 
be assessed by CogState Brief Battery  (CBB) and the CogState Schizophrenia Battery ( CSB) , 
and a functional outcome measure (UPSA- B total score).  
Blood samples for determination of plasma SEP -363856 and SEP -363854 concentrations will be 
collected at Visit 2E, 5E, 8E, and 11E. POPPK  analysis will be performed using plasma 
SEP-363856 concentrations; the results of which will be reported separately.  
Subjects who meet any discontinuation/withdrawal criteria will be terminated from the study. 
Upon termination from the study, hospitalization will be allowed for up to 7 days to stabilize the 
subject, if necessary. Prior authorization for hospitalization must be approved by the Medical 
Monitor. 
7.2. Treatment Assignment and Blinding  
This is an open- label study. All subjects will receive flexible dosing with SEP-363856 (25, 50, or 
75 mg /day).  
7.2.1. Emergency Unblinding Procedures  
This is an open- label study . 
7.3. Rationale  
7.3.1. Rationale for the Study Design 
This is an open-label extension study to further evaluate the long- term safety and tolerability of 
flexibly -dosed SEP -363856 (25, 50 or 75 mg ) over 26 weeks of treatment in adult subjects with 
schizophrenia who completed 4  weeks of double- blind treatment in Study SEP361-201. 
Long -term effectiveness  of SEP-363856 will also be evaluated. 
7.3.2. Rationale for the Dosages 
In the present study, dosing of SEP -363856 at 25, 50, or 75 mg /day for 26 weeks will be utilized  
based on observed safety and tolerability in previous studies. Dosages of 50 or 75 mg /day were 
evaluated in Study SEP 361-201. Selection of this dose range was guided by the maximum 
tolerated dose (MTD) determined for single doses of SEP -363856 administered to heal thy adult 
subjects in Study SEP 361-101 (50 mg); the MTD determined for single doses administered to 
adult subjects with schizophrenia in Study SEP 361-105 (75 mg ); by the single doses 
administered to healthy adult subjects (Studies SEP361-103 and SEP 361-104 [50 mg ]) which 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 31 13 October 2017 were found to have robust CNS activity). Study SEP361-108 in narcolepsy subjects  also 
demonstrated CNS activity (i.e., REM  suppression) at 25 and 50 mg . In addition, dose selection 
is supported by acceptable safety and tolerability data fro m the 7 -day (10  ‚Äì 75 mg ) and open 
label 28 -day (75 mg ) MAD study (Study SEP361-106, Parts 1 and 2) in adult subjects with 
schizophrenia. 
7.4. Prevention of Missing Data  
In an effort to minimize the number of subjects who are terminated from the study prior to s tudy 
completion, the following study design and conduct elements are implemented: 
‚Ä¢ allowance of a dose reduction (from 75 to 50 mg /day or from 50 to 25 mg /day) for drug 
tolerability purposes 
‚Ä¢ allowance of some concomitant psychotropic medications during stud y participation  
‚Ä¢ train the study centers on the importance of continued follow-up and on the informed 
consent process, ensuring subjects understand the commitment they are making, 
including the intent to complete the trial 
‚Ä¢ monitor data collection for adherence during the study 
Please see Section  15.3 for statistical considerations related to missing data.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 32 13 October 2017 8. SELECTION OF SUBJECTS 
8.1. Subject Inclusion Criteria 
To qualify for participation, subjects must meet all of the following inclusion criteria:  
1. Subject must give written informed consent and privacy authorization prior to 
participation in the study and able to comply with the protocol, in the opinion of the investigator. Separate consent will be obtained from a caregiver or legal guardian if 
required by local law.  
2. Subject has completed Study SEP361-201 through Week 4. 
3. Subject has not taken any medication other than the study drug for the purpose of controlling schizophrenia symptoms during Study SEP361-201. 
4. Female subject must have a negative urine pregnancy test at Visit 7 of Study 
SEP361-201; females who are post- menopausal (defined as at least 12  months of 
spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test. Female subject of reproductive potential agrees to remain abstinent or use highly effective  and reliable contraception 
throughout the study and for at least 30 days after the last dose of study drug has been taken (See Section  21 Appendix II Highly Effective Contraceptive procedures). In the 
Investigator's judgment, the subject will adhere to this requirement. 
5. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use highly effective methods of birth control from screening until at 
least 30 days after the last study drug administration.  
8.2. Subject Exclusion Criteria  
To qualify for participation, subjects must not meet any of the following exclusion criteria:  
1. Subject answers "yes" to "suicidal ideation" Item  4 (active suicidal ideation with some 
intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C- SSRS assessment at Visit  7 of Study SEP361-201. Subjects who 
answer "yes" to this question must be referred to the Investigator for follow-up evaluation. 
2. Subject has a clinically significant abnormality including physical examination, vital 
signs, ECG, or laboratory test at Visit 7 of Study SEP361-201 that the investigator in 
consultation with the medical monitor considers to be inappropriate to allow participation in the study. 
3. Subject has a positive urine drug screen (UDS) or breath alcohol test at Visit 7 of Study 
SEP361-201. 
4. Subject is pregnant or lactating.  
5. Subject is at high risk of non-compliance in the Investigator's opinion. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 33 13 October 2017 6. Subject is in the opinion of the Investigator, unsuitable in any other way to participate in 
this study.  
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 34 13 October 2017 9. STUDY DRUG MATERIALS  AND MANAGEMENT
9.1. Description of Study Drug
Table 5: Investigational Product 
Attribute  Investigational Product  
Product name SEP-363856 SEP-363856 SEP-363856 
Dosage form  Capsule Capsule Capsule 
Unit dose 25 mg  50 mg  75 mg  
Route of 
administration  Oral Oral Oral 
Physical description  Size #0, Swedish Orange Capsule Size #0, Swedish Orange Capsule Size #0, Swedish Orange Capsule  
Excipients None None None 
9.2. Study Drug Packaging and Labeling  
9.2.1. Package Description  
Study drug will be provided in one- week blister cards  containing 9 SEP -363856 25 mg, 50 mg, 
or 75 mg capsules (7  days  + 2 extra days).  
9.2.2. Labeling Description 
All packaging for the s tudy drugs will be labeled with: 
‚Ä¢Protocol number
‚Ä¢Sponsor‚Äôs name and address
‚Ä¢Compound/Code or name of investigational drug and dos age form
‚Ä¢Contents (eg , number of capsules )
‚Ä¢Investigational Drug/caution statement
‚Ä¢Instructions for use and storage
‚Ä¢Batch number
‚Ä¢Blank space to record visit number
‚Ä¢Blank space for subject identifiers
‚Ä¢Period of use (as required)
‚Ä¢Unique medication/kit ID number
‚Ä¢Investigator information (if needed)
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 35 13 October 2017 9.3. Study Drug Storage  
All study drug should be stored at United States Pharmacopeia ( USP) controlled room 
temperature 20¬∞C to 25¬∞C (68¬∞F to  77¬∞F); excursions are permitted from 15¬∞C to 30¬∞C (59¬∞F to 
86¬∞F). 
9.4. Dispensing of  Study Drug  
An Interactive Response System (IXRS) will be used to manage subject enrollment. The IXRS is 
an integrated web -based subject and drug management system.  
Study drug blister cards will be assigned by the IXRS based on the treatment schedule and  dose 
adjustment criteria. The IXRS will generate instructions for which medication number to assign 
to a subject. Each subject will be dispensed one or four 9-day blister cards per scheduled visit depending on the timing of the next scheduled visit (see  Table 2 ). 
Subjects will take one capsule of study drug  per day at approximately the same time  each 
evening before bed -time. Study drug may be t aken with or without food. 
Study drug  should be maintained under the stri ct control of qualified site staff at all times. 
Appropriate guidelines should be followed in proper dispensation to the study participant. Proper handling and storage should be followed. IXRS drug dispensing guidelines should be followed for dispensing st udy drug to the subject, in addition to all accountability records where required. 
Specific User Manuals will be supplied.  
9.5. Study Drug Accountability  
The Investigator or designee is responsible for storing the study drug in a secure location and for 
maintaining adequate records of drug disposition that includes the dates, quantity, and use by 
subjects. If the study is stopped for any reason or completed, all unused supplies of drug will be 
returned to the Sponsor, unless other instructions are provided in writing by Sponsor/contract research organization (CRO). 
Upon receipt of study drug, the Investigator or designee will inventory the supplies and verify 
receipt of supplies. The site will perform an acknowledgement of receipt via the IXRS, confirming the date of receipt, inventory and condition of study drug received. 
The Clinical Inventory Management System (CIMS) will be used for the accountability of the 
study drug at the clinica l site. The Investigator or designee will maintain the inventory for 
accountab ility within CIMS, including CTM dispensation, return and availability of CTM 
received. The Investigator or designee will collect and document all used and unused study drug  
from study subjects at appropriate study visits.  
9.6. Study Drug Handling and Disposal  
Study drug  will not be dispensed to any person who is not a study subject under this protocol. 
The Investigator or designee is required to return all unused study drug to the Sponsor or 
designee as instructed . The Investigator or designee is required to maintain copies of study drug 
shipping receipts, drug accountability records, and records of return or final disposal of the s tudy 
drug in accordance with local regulatory requirements. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 36 13 October 2017 10. TREATMENT OF SUBJECTS
10.1. Study Drug 
All study drug doses will consist of capsule(s) containing SEP -363856 administered orally.  
Subjects m ay take study drug with or without food at appr oximately the same time each evening 
before bed -time.  
Time and date of food intake must be recorded on Day 8, Day  29, Day  113, and Day  183 when 
blood samples are collected for determination of SEP -363856 and SEP -363854 concentrations. 
10.1.1. Dosage Adjustment Criteria  
All subjects will receive open -label SEP-363856 50 mg /day from Day  1 through Day 3. 
Beginning on Day  4, flexible dosing ranging from 25 ‚Äì 75 mg/day is permitted , if deemed 
clinically necessary (for reasons of safety, tolerability, or efficacy) by the Investigator . On Day  4, 
subjects are permitted (but not required) to titrate up to 75  mg/day. Thereafter, if a dose increase 
is necessary to opti mize efficacy it should occur at regular scheduled study visits based on 
Investigator judgement. Day 4 dosing changes will occur at an unscheduled visit. Thereafter, an 
increase in dose should occur at weekly intervals and in increments of one dose level a t a time to 
a maximum dose of 75 mg /day. Dose reduction for tolerability purposes is allowed  at any time 
during the study. 
10.2. Treatment Compliance  
The Investigator will record the dose of the study drug and the dates of the initial and final 
administration  for each  dose. 
Compliance must be monitored closely and determined at each visit. Subjects will be instructed 
to bring all used blister cards and unused study drug with them to each visit. Compliance will be 
assessed by counting capsules and dividing the actual number of doses taken (per capsule count) 
by the number of doses the subject should have taken within a visit period and multiplying by 100. All subjects will be reminded of the importance of strict compliance with taking study 
drug for the effectiveness of treatment and for the successful outcome of the study. Subjects who miss more than 25% of scheduled doses or take more than 125% of the scheduled doses will be considered noncompliant. Evidence of noncompliance must be immediately reported to the 
Clinical Research Associate (CRA) and/or Medical Monitor.  
10.3. Concomitant Medications and Restrictions  
The following information on a ll medication  administered between  Visit 1E and Visit 11E or at 
discontinuation will be recorded on the CRF: Medication  name, dose, frequency, route, 
start date, stop date, and indication. 
Information on the format and version of coding dictionary is provided in the Data Management 
Plan (DMP).  All medications will be coded using World Health Organization ‚Äì Drug Dictionary 
(WHO- DD). 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 37 13 October 2017 Table 6: Concomitant Medications/Therapies: Use During Study  
Type of Drug  Baseline to End of Treatment  
Antipsychotic drugs other than study drug  Not Permitted  
Mood stabilizers, antidepressants, or antiepileptic drug s Not Permitted  
Fluoxetine or MAO inhibitors  Not Permitted  
Clozapine  Not Permitted  
Investigational products for other clinical or post- marketing studies  Not Permitted  
Electroconvulsive therapy  Not Permitted  
Antiparkinsonian drugs  Permitteda 
Anti-anxiety and Sedative Hypnotic agents  Permitteda 
Drugs for acute or mild, chronic medical conditions  Permitteda 
Non-prescription pain medications  Permitted  
Herbal supplements (for psychotropic reasons)  Not Permitted  
Abbreviations: MAO  = Monoamine oxidas e. 
a Permitted doses of these medications are specified in  Section 10.3.1 and Section  10.3.2 . 
10.3.1. Conc
omitant Nonpsychotropic Medications 
Medications for short- term treatment of an acute  medical condition are allowed after consultation 
with the Medical Monitor.  Non-psychotropic medications used to treat mild, chronic medical 
conditions is allowed if the dose and regimen have been stable (¬± 25%) for at least 30 days. The 
concomitant medication dose may change, as needed, after enrollment (or be discontinued). Œí-adrenergic antagonists used to treat stable hypertension may be continued. In addition, use of 
non-prescription pain medications (eg, aspirin, acetaminophen) are allowed during all phases of 
the study provided these medications do not have a propensity for psychotropic effects and do not interfere with the evaluation of study drug . Female subjects may use oral, patch, or IUD 
hormonal contraceptives, or progestin implant or injection (detailed information on allowed contraceptives are defined in Section  21 Appendix II). 
10.3.2. Concomitant Psychotropic Medications  
All antidepressants and mood stabilizers (eg, lithium, divalproex/valproic acid, carbamazepine, 
etc.) ar e not allowed during the study. 
Treatment with benztropine (benzotropine outside the US) up to 6 mg/day will be permitted, as 
needed, for movement disorders. In cases where benztropine is not available or a subject has had 
an inadequate response or intolerability to benztropine treatment, the following medications may 
be used to treat acute extrapyramidal symptoms (EPS): biperiden (up to 16 mg/day) or trihexyphenidyl (up to 15 mg/day) or diphenhydramine (up to 100 mg/day). Treatment with 
propranolol (up to 120 mg/day) will be per mitted as needed for akathisia.  
Medications used to treat movement disorders should not be given prophylactically. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 38 13 October 2017 ‚Ä¢Concomitant use of lorazepam, temazepam, eszopiclone, zopiclone, zaleplon,
zolpidem and zolpidem CR is permitted at the discretion of the Investigator with the
following rest rictions:
‚àí Lorazepam (or equivalent benzodiazepine) is permitted for clinically significant
anxiety/agitation or as a sedative/hypnotic up to a maximum daily dose of 6 mg/day. Intramuscular lorazepam is permitted up to 4  mg/day for acute 
anxiety/agitation, as clinically indicated . Lorazepam should be used sparingly, 
when clinically required, per investigator judgment. 
‚àí Temazepam (‚â§  30 mg/day), eszopiclone (‚â§ 3 mg/day) , zopiclone (‚â§  7.5 mg/day) , 
zaleplon (‚â§ 20mg/day), zolpidem (‚â§ 10 mg/day for males; ‚â§  5 mg/da y for 
females), and zolpidem CR (‚â§ 12.5 mg/day for males; ‚â§ 6.25 mg/day for females) 
may be administered at b edtime for insomnia, as needed. 
‚àí Hypnotic agents should be administered no more than once nightly and should not 
be used in combination. 
The date and time of the last dose taken prior to scheduled assessments must be recorded at each 
visit. Subjects should be encouraged to avoid taking these medications within 8 hours of scheduled efficacy assessments.  
Medications used for the treatment of anxiety/agi tation and insomnia (eg, lorazepam and 
zolpidem) should not be used in close temporal proximity (defined as administration within 2 hours of each other). In regions that do not have the specified drugs available, similar drugs at 
equivalent dosages will be permitted as described in the Operations Manual or in consultation 
with the Medical Monitor.  
Subjects who require treatment with one or more of the restricted concomitant medications 
(including other antipsychotics or anxiolytics [lorazepam or equivalent above protocol- specified 
limits]) will be discontinued (as appropriate) from the study.  
10.3.3. Prohibited Medications  
All antipsychotics (except for study drug treatment), antidepressants and mood stabilizers (eg, lithium, divalproex/valproic acid, carbamazepine, lamotrigine, etc.) are not permitted during the 
study.  
Subjects who require treatment with one or more of prohibited concomitant medications (including antipsychotics [other than study drug treatment] or anxiolytics [lorazepam or 
equivalent above protocol- specified limits]) will be discontinued (as appropriate) from the study. 
Limited use of these medications immediately prior to study discontinuation is permitted and 
will not constitute a protocol deviation. 
10.3.4. Prohibited Therapies  
Subjects must not receive electroconvulsive therapy  (ECT)  during the study. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 39 13 October 2017 10.4. Other Restrictions  
Subjects must abstain from alcohol from enrollment through the end of the study. 
10.5. Description of Study Periods and Hospital Discharge  
10.5.1. Description of Study Periods  
The periods of the study, their duration, and subject status are provided below in Table 7. 
Table 7: Description of Study Periods  
Study Period Visit Number Study Week / Day  Inpatient/Outpatient  
Basel ine Visit 1E Day 1 Inpatient optional (Investigator 
discretion)  
Open Label  
Treatment Period  Visit 2E Week  1 / Day  8 ¬± 2 Outpatient  
Visit 3E Week  2 / Day  15 ¬± 2 Outpatient  
Visit 4E  Week  3 / Day  22 ¬± 2 Outpatient  
Visit 5E Week  4 / Day  29 ¬± 3 Outpatie nt 
Visit 6E Week  8 / Day  57 ¬± 3 Outpatient  
Visit 7E Week  12 / Day  85 ¬± 3 Outpatient  
Visit 8E Week  16 / Day  113 ¬±  3 Outpatient  
Visit 9E Week  20 / Day  141 ¬±  3 Outpatient  
Visit 10E Week  24 / Day  169 ¬±  3 Outpatient  
Visit 11E Week  26 / Day  183 ¬±  3 Outpatient  
Follow -up 
(End of Study)  Visit 12E Week  27 / Day 190 ¬±  2 
7 days after last dose  
(subjects who complete or 
discontinue)  Inpatient optional (Investigator 
discretion)  
10.5.2. Hospital Discharge During the Study  
To facilitate enrollment and to optimize tre atment compliance, an optional inpatient 
hospitalization period, at the I nvestigat or‚Äôs discretion, can occur during the first week of open-
label treatment.  Subjects are eligible for hospital discharge if they meet all of the following 
criteria:  
1. The subject is considered by the Investigator to be clinically stable and appropriate for
discharge to an outpatient or community setting.
2. There is no evidence of imminent danger to self or others.
3.Subject answers ‚Äúno‚Äù to ‚ÄúSuicidal Ideation‚Äù item  4 (active suicidal ideation with some
intent to act, without specific plan) and item 5 (active suicidal ideation with specific plan
and intent) on the C- SSRS at time of evaluation.
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 40 13 October 2017 4. An outpatient environment is available that ensures continued safety for the subject and
conti nued contact with the treatment team for the remainder of the protocol.
5.A reliable informant (family member or caregiver) agrees to confirm adherence to study
drug during outpatient study participation.
If the subject cannot be transitioned to an outpatient setting, they must be discontinued from the 
study. After completion of the follow-up visit or upon study discontinuation; all subjects will be referred for appropriate continued treatment and follow- up care as determined by the 
Investigator. 
10.6. Guidance for  Overdose  
Potential overdose to SEP -363856 has not been evaluated. Appropriate supportive measures 
should be instituted and close medical supervision and monitoring should continue until the subject recovers. Consider the possibility of multiple-drug overdose.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 41 13 October 2017 11. STUDY ASSESSMENTS
A study schematic is presented in Figure  1. A summary of assessments to be conducted at each 
visit is  presented in Table 2. 
11.1. Demographics and Baseline Characteristics  
Demographics (date of birth, sex, ethnicity, race), height, and medical and psychiatric history 
collected at Visit 1 of Study SEP361-201 will be carried over . Prior and current medications in 
Study SEP361-201will be carried over and will also be collected  in the present study. 
11.2. Prior and Concomitant Medication Review 
See Section  10.3 for a complete description of medications permitted during the study. Site study 
staff will record all medications used to treat sch izophrenia in the eCRF. Also, the following 
parameters will be recorded for all concomitant medications: drug name, route of administration, 
total daily dose, unit, frequency, start/stop dates, indication, and whether the medication was 
started after last dose of study drug . The prior and concomitant medications will subsequently be 
coded using the World Health Organization Drug Dictionary (WHO- DD).  
11.3. Efficacy Assessments  
11.3.1. Positive and Negative Syndrome Scale (PANSS) 
The PANSS is an interview -based measure of the severity of psychopathology in adults with 
psychotic disorders. The measure is comprised of 30 items and 3  scales: the Positive scale 
assesses hallucinations, delusions, and related symptoms; the Negative scale assesses emotional 
withdrawal, lack of mo tivation, and similar symptoms; and the General Psychopathology scale 
addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored 
Likert scale from 1  - 7, where values of 2 and above indicate the presence of progressively mor e 
severe symptoms, is used to score each item. Individual items are then summed to determine 
scores for the 3  scales, as well as a total score. A Composite scale score (Positive scale score 
minus Negative scale score) can also be calculated to show the rel ative valence of positive and 
negative symptoms. Total time required for the PANSS interview and scoring is approximately 30 ‚Äì 40 minutes ( Guy-1976, Kay-1994;  Opler -1992; Perkins-2000). PANSS raters will be 
required to meet specific training and education criteria before they are certified to rate for this study. In addition, raters will receive specific training and education regarding all of the assessments prior to study initiation.  
11.3.2. Brief Negative Symptom Scale (BNSS)  
The BNSS  is a rating scale to measur e the current level of severity of negative symptoms in 
schizophrenia and schizoaffective disorder . The measure is comprised of 13 individual items  and 
5 domain scores (blunt ed affect , alogia, avolition, anhedonia, and asociality ). The 5  domain 
scores provide a summary score and the 13 individual items provide a composite total score 
(ranging from 0  to 78). Each of the items are scored  on a Likert -type 7-point scale from 0 - 6, 
where values of 0  indicates symptom is absent and a value of 6 means the symptom is a severe 
form. The number of items varies per domain. BNSS  raters will be required to meet specific 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 42 13 October 2017 training and education criteria before they are certified to rate for this study. In addition, raters 
will receive specific training and education regar ding all of the assessments prior to study 
initiation.  
11.3.3. Montgomery -Asberg Depression Rating Scale (MADRS)  
The MADRS is a clinician -rated assessment of the subject‚Äôs level of depression. The measure 
contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and 
appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal 
thoughts. Each item is scored in a range of 0 to  6 points, with higher scores indicating increased 
depressive symptoms. The Structured Interview Guide for the MADRS (SIGMA) 
(Williams -2008) will be used for the administration of the MADRS assessment. T he MADRS 
will be administered by a qualified rater at the site.  
11.3.4. Clinical Global Impressions ‚Äì Severity Scale (CGI -S) 
The CGI-S is a clinician -rated assessment of the subject‚Äôs current illness state on a 7 -point scale, 
where a higher score is associated with greater illness severity. Following a clinical interview, 
the CGI-S can be completed in 1  to 2 minutes. The CGI -S will be admin istered by a qualified 
rater at the site.  
11.3.5. CogState Brief Battery (CBB) and CogState Schizophrenia Battery (CS B) 
The CBB will be completed at Visit 1E (ie, Baseline, which is the same day as Visit 7 of Study 
SEP361-201). The CBB assesses four domains. The D etection test (Attention Domain) measures 
speed of performance. The mean of the log10 transformed reaction times for correct responses 
are utilized to determine the score. Lower scores correspond to better performance. The 
Identification test (Information Processing Domain also measures speed of performance. The 
mean of the log10 transformed reaction times for correct responses are utilized to determine the 
score. Lower scores correspond to better performance. The One Card Learning test (Visual 
Learning Domain) measures accuracy of performance. Arcsine transformation of the proportion of correct responses are utilized to determine the domain score. Higher scores correspond to 
better performance. The One-back Memory test (Working Memory Domain) measures Arcsi ne 
transformation of the proportion of correct responses is  utilized to determine the domain score. 
Higher scores correspond to better performance. 
The CSB will be completed at Visit 7E (Week  12) and Visit 11E (Week  26). The CSB includes 
the four domains of the CBB and three additional domains. The Internal Shopping List (Verbal 
Learning Domain) measures the t otal number of correct responses made in remembering the list 
on three consecutive learning trials. Higher scores correspond to better performance. Groton Maze Learning (Problem Solving Domain) measures the t otal number of errors made in 
attempting to learn the same hidden pathway on five consecutive trials . Lower scores correspond 
to better performance. Social Emotional Cognition (Social Cognition Doma in) measures 
accuracy of performance. A rcsine transformation of the proportion of correct responses is 
utilized to determine the domain score. Higher scores correspond to better performance. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 43 13 October 2017 11.3.6. University of California, San Diego, Performance- Based Skills Assessment -Brief 
(USPA-B) 
University of California, San Diego, Performance- Based Skills Assessment -Brief (USPA -B) 
assesses everyday functioning in persons with serious mental illness ( Mausbach -2007). The 
UPSA -B, consists of 2 subscales (communication and fina ncial). The UPSA -Brief is a measure 
of functional capacity in which patients are asked to role-play tasks in 2 areas of functioning: 
(1) communication and (2) finances. The UPSA -Brief requires approximately 10  ‚Äì 15 minutes to 
complete and will be administe red by a trained professional.  
11.4. Safety Assessments  
The Investigator or appropriate designee will review results of safety assessments on a regular 
basis and the Sponsor must be kept fully informed of any clinically significant findings either at 
baseline or subsequently during study conduct. 
11.4.1. Adverse Events  
Adverse events will be collected for each subject. Subjects should be queried in a non- leading 
manner, without specific prompting (eg, ‚ÄúHas there been any change in your health status since 
your last visit?‚Äù). See Section  12, Safety Reporting. 
AEs and SAEs will be monitored throughout the study at all visits. 
11.4.2. Clinical Laboratory Tests 
The clinical laboratory tests required by protocol are listed in  Section  22, Appendix III. 
Blood and urine samples will be collected for clinical laboratory tests. For detailed instructions 
regarding clinical laboratory procedures, sampling, and shipping guidelines refer to the Central 
Labor atory Instructions Manual. Samples will be processed at a central laboratory to ensure 
consistency. All clinical laboratories will be College of American Pathologists (CAP), Clinical 
Laboratory Improvement Amendments (CLIA) and/or other laboratory certific ations or 
equivalent accreditation documents. 
Any POC  (point of care) kits that are performed on site by study personnel rather than in a lab- 
must be CLIA waived and the study center  must possess a CLIA certificate of Waiver.  
11.4.3. Vital Signs  
Blood pressure and heart rate measurements will be taken in a sitting and standing position. 
Respiratory rate and temperature will also be measured and all measurements will be recorded in 
the eCRF. Clinically significant changes from the signing of the ICF should be captured as AEs in the eCRF.  
Supine systolic and diastolic blood pressures, respiratory rate, pulse rate, and oral temperature 
will be measured following 5 minutes of seated rest.  
Blood pressure and pulse rate should first be taken with the subject in the supine position after 
resting for ‚â• 5 minutes. Blood pressure and pulse rate will be taken again after standing for 2 to 
4 minutes. The same arm should be used during each assessment of blood pressure and pulse rate throughout the study. If a subject develops s ymptoms consistent with orthostatic hypotension 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 44 13 October 2017 (light-headedness, dizziness, or changes in sensorium upon standing) at any point, his or her 
supine and standing blood pressure and pulse rate should be collected at that time in the manner 
described above. Vital signs will be obtained prior to clinical laboratory collection and 
performance of an ECG.  
11.4.4. Electrocardiograms (E CGs) 
All ECGs will be obtained in the supine position, after the subject has been resting supine for at 
least 5 minutes. ECGs will be 12-lead with a 10-second rhythm strip. ECGs should be obtained 
prior to drawing blood samples. All attempts should be made to use the same ECG recorder for 
all visits within individ ual subjects. Refer to  Section  20 Ap pendix I for additional information. 
ECG parameters to be collected include ventricular heart rate (beats/min), QT interval (msec), PR interval (msec), QRS interval (msec) ,RR interval (msec), and overall ECG interpretation (Normal, Abnormal NCS, Abnormal CS).  
It is the responsibility of the Investigator to perform a safety review of the ECG data for changes 
from previous assessments and/or emergent cardiac dysfunction, and to determine subjects‚Äô eligibility for or continuance in the study. Abnormalities re quire comment as NCS or CS. 
Typically, CS designated events will be reported as adverse events.  
ECGs will be reviewed, signed and dated by the Investigator  after each ECG collection. The 
same physician should review all ECG reports for a given subject whenever possible. 
The original ECG tracing will be kept with subject‚Äôs source documentation. A copy may be 
collected by the Sponsor. 
11.4.5. Physical and Neurological Examination 
Full PE as well as a neurological examination will be performed. The PE includes an assessment 
of general appearance and a review of systems (dermatologic, head, eyes, ears, nose, 
mouth/throat/neck, thyroid, lymph nodes, respiratory, cardiovascular, gastrointestinal, extremities, musculoskeletal, neurol ogic, and psychiatric systems).  
The phys ical and neurological examination results at Visit 1 (screening) of Study SEP361-201 
will be carried over. All PE and neurological exam findings at screening of Study SEP361-201 will be captured in the medical history in the CRF. Any clinically significant changes from 
screening in Study SEP361-201, as determined by the Investigator, will be noted as AEs in the 
CRF.  
11.4.6. Height, Weight, and BMI 
Weight will be measured in kilograms. Weight will be measured in street clothes, without shoes 
and coat/jacket.  
Height in meters will be  carried over from study SEP361-201. Height will be measured without 
shoes. 
BMI for all visits will be derived within the Electronic Data Capture (EDC) system.  
Waist circumference will be measured in inches or centimeters and recorded in the eCRF.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 45 13 October 2017 11.4.7. Safety Scales  
11.4.7.1. Abnormal Involuntary Movement Scale (AIMS) 
The AIMS is a clinician -rated assessment of abnormal movements consisting of unobtrusive 
observation of the subject at rest (with shoes removed) and several questions or instructions 
directed toward the subject. Using a severity scale ranging from 0 (none) to 4 (severe), clinicians 
rate dyskinesia in several body regions, including the facial area, extremities, and trunk. There are two items related to dental status, as well as three global i mpression items assessing overall 
severity, incapacitation, and the subject‚Äôs awareness of abnormal movements ( Guy-1976; 
Munetz-1988). The AIMS raters will be required to meet specific credential and educational criteria before they are certified to rate f or this study. The AIMS will be administered by a 
qualified rater at the site.  
11.4.7.2. Barnes Akathisia Rating Scale (BARS) 
The BARS is a rating scale geared toward assessment of neuroleptic -induced akathisia, though it 
can be used to measure akathisia associated with other drugs as well. The BARS consists of four 
items, including one item assessing objective restlessness, two items targeting subjective restlessness (awareness and related distress), and one global clinical assessment item. All items are anchored an d utilize a 4 -point scale, except for the global rating which has a 6 -point scale 
(from absence of akathisia through severe akathisia). The subjective and objective items are summed to yield a total score. The BARS can be administered in about 10 minutes (Barnes -1989; Barnes -2003). The BARS will be administered by a qualified rater at the site.  
11.4.7.3. Simpson- Angus Scale (SAS)  
The SAS is a clinician -rated assessment of neuroleptic-induced Parkinsonism consisting of 
10 items. Items are anchor -based, rated on a 5-po int scale, and address rigidity, gait 
(bradykinesia), tremor, glabellar tap, and salivation ( Siddiqui-2009; Simpson-1970). The SAS 
will be administered by a qualified rater at the site.  A modified version of the SAS will be 
utilized for this study ( SAS). 
11.4.7.4. Columbia Suicide Severity Rating Scale ( C-SSRS) 
The C-SSRS is a tool designed to systematically assess and track suicidal adverse events 
(suicidal behavior and suicidal ideation) throughout the trial. The strength of this suicide classification system is in  its ability to comprehensively identify suicidal events while limiting 
the over-identification of suicidal behavior. The scale takes approximately 5 minutes to 
administer. The C- SSRS will be administered by a trained rater at the site. Subjects with Type  4 
or 5 suicidal ideation during the study will be discontinued from the study and referred to a 
mental health professional ( Posner-2007). For all visits the ‚ÄúSince Last Visit‚Äù version of the 
C-SSRS will be used. 
11.4.7.5. Drug Effect s Questionnaire (DEQ)  
A Drug Effe cts Questionnaire designed to  assess subjective effects will be completed by the 
subject. The DEQ consist of 3 questions scored on a visual analog scale (VAS). 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 46 13 October 2017 11.4.7.6. Pittsburg Sleep Quality Index (PSQI)  
The Pittsburgh Sleep Quality Index (PSQI) consists of 19 se lf-rated questions used to measure 
the quality and patterns of sleep in adults. It differentiates ‚Äúpoor‚Äù from ‚Äúgood‚Äù sleep quality by 
measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sl eep disturbances, use of sleeping medications, and daytime 
dysfunction over the last month ( Buysse  1989).  
11.5. Population Pharmacokinetic Assessments  
All blood samples for determination of plasma SEP-363856 and SEP-363854 concentrations will 
be obtained at the same time that other blood samples are taken whenever possible. The time and date of the 3 previous doses of study drug, date, and clock time of blood sampling must be 
recorded. Date and clock t ime of food intake must be recorded at Visit 2E, 4E, 8E, and 11E when 
blood samples are collected for determination of plasma SEP -363856 and SEP-363854 
concentrations. POPPK analysis will be performed using plasma SEP -363856 concentrations; the 
results of which will be reported separately.  The relationship between PANSS total score and 
plasma SEP -363856 exposure will be explored using population PK/pharmacodynamics (PD) 
methods, and reported separately. The impact of cytochrome (CYP) P450 CYP2D6 metabolizer 
status on SEP -363856 plasma exposure will be explored and reported separately.  See Section  23 
Appendix IV for details including instructions of processin g PK samples . 
11.6. Study Visits and Assessments 
See Table 2 Schedule of Assessments , for a summary of procedures at each study visit.  
11.6.1. Baseline: Visit 1E (Day 1) 
Visit 1E of the present study is on the same day as Visit 7 of Study SEP361-201. Subjects will be 
evaluated at the Open -label Baseline Visit to determine their eligibility for the  study. The 
following procedures will be conducted during this visit: 
‚Ä¢Obtain signed informed consent and privacy authorization from the subject beforeconducting any other visit procedures.
‚Ä¢Inclusion and exclusion criteria
‚Ä¢USPA -B
‚Ä¢Dispense study drug
Result s for the following study- related procedures will be carried over from the core study 
Week  4 visit and do not need to be performed for the Open- label Baseline visit:  
‚Ä¢Adverse events monitoring
‚Ä¢Prior/concomitant medication review
‚Ä¢Physical and neurological ex aminations
‚Ä¢Vital signs
‚Ä¢Weight and waist circumference
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 47 13 October 2017 ‚Ä¢ECG
‚Ä¢Clinical laboratory tests  (hematology, serum chemistry, serum prolactin, glycosylated
hemoglobin [HbA 1c], glucose panel and lipid panel)
‚Ä¢Blood sample for plasma SEP -363856 and SEP -363854
‚Ä¢Urine sampl e for urinalysis , urine drug screen ( UDS ), and urine pregnancy test
(human chorionic gondadotropin [ Œ≤-HcG ])
‚Ä¢PANSS
‚Ä¢BNSS
‚Ä¢MADRS
‚Ä¢C-SSRS
‚Ä¢CGI-S
‚Ä¢AIMS
‚Ä¢BARS
‚Ä¢SAS
‚Ä¢PSQI
‚Ä¢DEQ
‚Ä¢CBB
Procedures are to  be completed in the following order : 
1. PANSS (study center rater)
2.BNSS (study center rater)
3. MADRS (study center rater)
4. C-SSRS (study center rater)
5. CGI -S (study center rater)
6. AIMS/BARS/SAS
7. PSQI
8. DEQ
9. CSB
10. USPA -B
Note: With the exception of the DEQ and the USPA -B, all rating assessments will be  performed by the rater using a 
tablet. In the event that a tablet is not available, the rating assessments will be performed by the rater using a paper 
version of the assessment.  
Data such as demographics and height will be carried over from the Screening visit in 
Study SEP361-201. 
Further information on data carried over from Study SEP361 -201 will be addressed in the D ata 
Management Plan (DMP ). 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 48 13 October 2017 11.6.2. Visit 2E (Week 1; Day 8 ¬± 2) 
The following procedures will be conducted during this visit: 
‚Ä¢Dispense study drug
‚Ä¢Study drug accountability
‚Ä¢AE monitoring
‚Ä¢Prior/concomitant medications.
‚Ä¢Vital sign measurements (prior to ECG)
‚Ä¢Weight and waist circumference
‚Ä¢Perform standard 12-lead ECG
‚Ä¢Fasted blood s amples for clinical laboratory evaluation (hematology, serum
chemistry, s erum prolactin, glycosylated hemoglobin [HbA 1c], glucose panel  and
lipid panel).
‚Ä¢Blood sample for plasma SEP-363856 and SEP -363854
‚Ä¢Urine sample for urinalysis , UDS , and Œ≤- hcG (for female subjects).
‚Ä¢PANSS
‚Ä¢BNSS
‚Ä¢MADRS
‚Ä¢C-SSRS
‚Ä¢CGI-S
‚Ä¢AIMS
‚Ä¢BARS
‚Ä¢SAS
‚Ä¢PSQI
A telephone contact will be made by a member of the research staff to the subject between 
Week  1 and Week  2 to monitor clinical symptoms and adverse events. If subject appears to be 
symptomatic  during the telephone contact, an unscheduled visit will be made as early as possible 
(see Section  11.6.11).  
11.6.3. Visit 3E (Week 2; Day 15 ¬± 2) 
The following procedures will be conducted during this visit: 
‚Ä¢Dispense study drug
‚Ä¢Study drug accountability
‚Ä¢AE monitoring
‚Ä¢Prior/concomitant medic ations
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 49 13 October 2017 ‚Ä¢Urine sample for Œ≤ -hcG (for female subjects)
‚Ä¢PANSS
‚Ä¢BNSS
‚Ä¢MADRS
‚Ä¢C-SSRS
‚Ä¢CGI-S
‚Ä¢AIMS
‚Ä¢BARS
‚Ä¢SAS
11.6.4. Visit 4E (Week 3; Day 22 ¬± 2) 
The following procedures will be conducted during this visit: 
‚Ä¢Dispense study drug
‚Ä¢Study drug accountability
‚Ä¢AE monitoring
‚Ä¢Prior/co ncomitant me dications
‚Ä¢Vital sign measurements
‚Ä¢Weight and waist circumference
‚Ä¢Urine sample for Œ≤ -hcG (for female subjects)
‚Ä¢PANSS
‚Ä¢BNSS
‚Ä¢MADRS
‚Ä¢C-SSRS
‚Ä¢CGI-S
‚Ä¢AIMS
‚Ä¢BARS
‚Ä¢SAS
11.6.5. Visit 5E (Week 4; Day 29 ¬± 3) 
The following procedures will be conducted during these visi ts: 
‚Ä¢Dispense study drug
‚Ä¢Study drug accountability
‚Ä¢AE monitoring
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 50 13 October 2017 ‚Ä¢ Prior/concomitant medications 
‚Ä¢ Physical and neurological examinations  
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Weight and waist circumference  
‚Ä¢ Perform standard 12-lead ECG  
‚Ä¢ Fasted blood samples for clinical laboratory evaluation (hematology, serum 
chemistry, serum prolactin, glycosylated hemoglobin [HbA 1c], glucose panel and 
lipid panel) 
‚Ä¢ Blood sample for plasma SEP-363856 and SEP -363854 
‚Ä¢ Urine sample for urinalysis, UDS, and Œ≤- hcG (for female subjects).  
‚Ä¢ PANSS  
‚Ä¢ BNSS  
‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
‚Ä¢ PSQI  
A telephone contact will be made by a member of the research staff to the subject  at Weeks  5 
and Week  7 to monitor clinical symptoms and adverse events.  If subject appears to  be 
symptomatic  during the telephone contact, an unscheduled visit will be made as early as possible 
(see Section  11.6.11).  
11.6.6. Visit 6E (Week 8; Day 57 ¬± 3) and Visit  7E (Week 12; Day 85 ¬± 3) 
The following procedures will be conducted during these visits: 
‚Ä¢ Dispense study drug 
‚Ä¢ Study drug accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
‚Ä¢ Physical and neurological examinations : Week  8 (Day  57) only 
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Weight and waist circumference  
‚Ä¢ Perform standard 12-lead ECG  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 51 13 October 2017 ‚Ä¢ Urine sample for Œ≤ -hcG (for female subjects)  
‚Ä¢ PANSS  
‚Ä¢ BNSS  
‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
‚Ä¢ PSQI: Week  12 (Day 85) only 
‚Ä¢ CSB: Week  12 (Day 85) only  
‚Ä¢ USPA -B: Week  12 (Day 85) only 
A telephone contact will be made by a member of  the research staff at Weeks  9, 11, 13, and 15 to 
monitor clinical symptoms and adverse events. If subject appears to be symptomatic during the 
telephone contact, an unscheduled visit will be made as early as possible (see Section  11.6.11).  
11.6.7. Visit 8E (Week 16; Day 113 ¬± 3) 
The following procedures will be conducted during these visits: 
‚Ä¢ Dispense study drug 
‚Ä¢ Study drug accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
‚Ä¢ Physical and neurological examination  
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Weight and waist circumference  
‚Ä¢ Perform standard 12-lead ECG  
‚Ä¢ Fasted blood samples for clinical laboratory evaluation (hematology, serum chemistry, serum prolactin, glycosylated hemoglobin [HbA
1c], glucose panel and 
lipid panel) 
‚Ä¢ Blood sample for plasma SEP-363856 and SEP -363854 
‚Ä¢ Urine sample for urinalysis , UDS , and Œ≤- hcG (for female subjects)  
‚Ä¢ PANSS  
‚Ä¢ BNSS  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 52 13 October 2017 ‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
A telephone contact will be made by a member of the research staff at Weeks  17 and 19. If 
subject appears to be symptomatic during the telephone contact, an unscheduled visit will be 
made as early as possible  (see Section  11.6.11).  
11.6.8. Visit 9E (Week 20; Day 141 ¬± 3) and Visit  10E (Week 24; Day 169 ¬± 3) 
The following procedures will be conducted during these visits: 
‚Ä¢ Dispense study drug 
‚Ä¢ Study drug  accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Weight and waist circumference  
‚Ä¢ Perform standard 12-lead ECG  
‚Ä¢ Urine sample for Œ≤ -hcG (for female subjects)  
‚Ä¢ PANSS  
‚Ä¢ BNSS  
‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
‚Ä¢ PSQI: Week  24 (Day 169) only 
A telephone contact will be made by a member of the research staff at Weeks  21, 23, and 25 to 
monitor clinical symptoms and adverse events. If subject appears to be symptomatic during the 
telephone contact, an unscheduled visit will be made as early as possible (see Section 11.6.11). 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 53 13 October 2017 11.6.9. Visit 11E (Week 26; Day 183 ¬± 3, Early Termination) 
The following procedures will be conducted during this visit: 
‚Ä¢ Study dr ug accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
‚Ä¢ Physical and neurological examination  
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Weight and waist circumference  
‚Ä¢ Perform standard 12-lead ECG  
‚Ä¢ Fasted blood samples for clinical laboratory evaluation (hematology, serum 
chemistry, serum prolactin, glycosylated hemoglobin [HbA 1c], glucose panel and 
lipid panel) 
‚Ä¢ Blood sample for plasma  SEP -363856 and SEP -363854 
‚Ä¢ Urine sample for urinalysis , UDS , and Œ≤ hcG (for female subjects) 
‚Ä¢ PANSS  
‚Ä¢ BNSS  
‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
‚Ä¢ PSQI  
‚Ä¢ DEQ  
‚Ä¢ CSB 
‚Ä¢ USPA -B 
11.6.10. Visit 12E (Week 27; Day 190 ¬± 2, Follow- up, End of Study)  
All subjects will have a follow -up prior to discharge (7 ¬± 2 days) after their last dose of study 
drug. The following procedures will be conducted during this visit: 
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications.  
‚Ä¢ Vital sign measurements (prior to ECG)  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 54 13 October 2017 ‚Ä¢ Urine sample for Œ≤- hcG (for female subjects)  
‚Ä¢ C-SSRS  
‚Ä¢ DEQ  
‚Ä¢ PSQI  
11.6.11. Unscheduled Visit (Subjects Who Appear Symptomatic during Telephone 
Contacts)  
If subject appears to be symptomatic during a telephone contact, an unscheduled visit will be 
made as early as possib le. The following procedures will be conducted during this visit: 
‚Ä¢ Study drug accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
‚Ä¢ Physical and neurological examination  
‚Ä¢ Vital sign measurements (prior to ECG)  
‚Ä¢ Perform standard 12-lead ECG  
‚Ä¢ Physical and n eurological examination  
‚Ä¢ Fasted blood samples for clinical laboratory evaluation (hematology, serum chemistry, serum prolactin, glycosylated hemoglobin [HbA
1c], glucose panel and 
lipid panel) 
‚Ä¢ Urine sample for urinalysis , UDS , and Œ≤ hcG (for female subjects) 
‚Ä¢ PANSS  
‚Ä¢ BNSS  
‚Ä¢ MADRS  
‚Ä¢ C-SSRS  
‚Ä¢ CGI-S 
‚Ä¢ AIMS  
‚Ä¢ BARS  
‚Ä¢ SAS 
If a subject titrates up to 75  mg/day on Day 4 (permitted but not required) an unscheduled visit 
must occur. The following procedures will be conducted during this visit: 
‚Ä¢ Study drug accountability  
‚Ä¢ AE monitoring 
‚Ä¢ Prior/concomitant medications  
Other assessments are not required on Day 4, but are permitted , based on Investigators judgment. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 55 13 October 2017 12. SAFETY R EPORTING
12.1. Definitions 
12.1.1. Adverse Events  
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related . 
Untoward medical occurrences that occur between the time of signing the ICF and first drug 
administration are pre -treatment events. Those that occur after first adminis tration of study drug 
are considered AEs.  
An AE can , therefore, be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease occurring after the administration of a medicinal (investigational) 
product, whether or not considered related to the medicinal (investigational) product. AEs may include the onset of new illness and the exacerbation of pre-existing conditions. A Es will be 
collected from after first administration of study drug to the last study visit. 
The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs/symptoms. 
12.1.2. Serious Adverse Events  
A serious adverse event (SAE) is an AE that meets one or more of the following criteria:  
‚Ä¢Results in death.
‚Ä¢Is life-threatening.
‚Ä¢Requires hospitalization or prolongation of existing hospitalization.
‚Ä¢Results in persistent or significant disability  or incapacity.
‚Ä¢Is a congenital anomaly  or birth defect.
‚Ä¢Is an important medical event that may jeopardize the subject  or may require a
medical or surgical intervention to prevent one of the outcomes listed above.
Examples of such medical events include allergic bronchospasm requiring intensive
treatment in an emergency room or at home, blood dyscrasias or convulsions  that do
not result in inpatient hospitalization .
The term "severe" is often used to describe the severity of a specific event (as in mild, moderate, 
or severe myo cardial infarction)  (see Section  12.3); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as 
"serious," which is based on subject /event out come or action criteria usually associated with 
events that pose a threat to a subject 's life or functioning as defined by the criteria above. 
During the study, if a subject  has a hospitalization or procedure (eg, elective surgery) that was 
scheduled befor e the study entry, ie, before informed consent for an event/condition that 
occurred before the study, the hospitalization is considered a therapeutic intervention and not the 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 56 13 October 2017 result of a SAE. However, if the event/condition worsens during the study, it should be reported 
as an AE (or SAE, if the event/condition results in a serious outcome such as prolongation of 
hospitalization).  
Life-threatening means that the subject was, in the view of the Investigator, at immediate risk of 
death from the event as it occurred. This definition does not include an event that had it occurred in a more severe form might have caused death.  
SAE criteria information will be captured on the CRF. 
12.2. Objective Findings 
Clinically significant abnormal objective findings (eg, clinical laboratory value, ECG value, and 
physical examination observation) will also be recorded as  AEs. 
When a clear diagnosis is available that explains the objective findings, this diagnosis will be 
recorded as the AE, and not the abnormal objective finding (eg , viral hepatitis will be recorded as 
the AE, not transaminase elevation). If a definite diagnosis is not available, then record the sign (eg, clinically significant elevation of transaminase levels) or symptom (eg, abdominal pain) as the AE.  
Clinical laboratory test results will be reviewed by the Investigator. The Investigator must 
determine the clinical significance of all out of range values. Clinical laboratory test with possibly drug- related or clinically relevant abnormal values of uncertain causalit y may be 
repeated. Any abnormal values that persist should be followed at the discretion of the Investigator. Laboratory reports will be initialed and dated on all pages by the Investigator. 
Clinical Laboratory Tests Outside the Normal Range: Any value outside the normal range will be 
flagged for the attention of the Investigator or appropriate designee at the study center. The 
Investigator or appropriate designee will indicate whether or not the value is of clinical 
significance. If the result of any test (or repeat test, if done) from the samples taken is indicated 
as clinically significant and is not covered by the inclusion criteria in Section  8.1, the subject will 
not be allowed into the study. Additional test ing during the study may be done if medically 
indicated. If a clinically significant abnormality is found in the samples taken after dosing, 
during the study, and/or at the Follow-Up Visit, this should be recorded as an AE and the subject 
will be followed until the test(s) has (have) normalised or stabilised.  
All on -site ECG tracings and ECG over -read reports will be reviewed by the Investigator. The 
Investigator must determine the clinical significance of all abnormal ECG s. ECG with possibly 
drug- related or clinically relevant abnormal findings of uncertain causality  may be repeated . Any 
abnormal ECGs that persist should be followed at the discretion of the Investigator. ECG 
tracings will be initialed and dated on all pages by the Investigator. 
12.3. Collection and Recording of Adverse Events  
All pre -treatment events and AEs must be recorded in the subject‚Äôs study records/source 
documents in accordance with the Investigat or‚Äôs normal clinical practice. All pre -treatment 
events and AEs/all AEs must be recorded on the CRF.  
All AEs will be followed until resolution, stabilization of the condition, the event is otherwise 
explained, or the subject is lost to follow-up. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 57 13 October 2017 Each AE is to be evaluated for duration, severity , frequency , seriousness,  action taken with the 
study treatment, outcome, and causal relationship to the s tudy treatment. Definitions for severity , 
frequency , action taken with the study treatment, outcome, and causal relationship to the s tudy 
treatment  are presented below.  
The severity  of AE:  
‚Ä¢Mild  - Ordinari ly transient symptoms that do not influence performance of subject‚Äôs
daily activities. Other t reatment is not ordinarily indicated.
‚Ä¢Moderate - Marked symptoms sufficient to make the subject uncomfortable.
Moderate influence on performance of subject‚Äôs dail y activities. Other treatment may
be necessary.
‚Ä¢Severe - Symptoms cause considerable discomfort. Substantial influence on subject‚Äôsdaily activities. May be unable to continue the s tudy, and other treatment may be
necessary.
The frequency  of AE : 
‚Ä¢Once ‚Äì an isolated episode.
‚Ä¢Intermittent  ‚Äì occurs on two or more separate occasions.
‚Ä¢Continuous  ‚Äì does not abate from date of onset to date of resolution.
The action taken  with the s tudy treatment: 
‚Ä¢Drug Interrupted  ‚Äì Study drug stopped temporarily.
‚Ä¢Drug Withdrawn  ‚Äì Study drug stopped permanently.
‚Ä¢Dose Reduced.
‚Ä¢Dose Increased.
‚Ä¢Dose Not Changed.
‚Ä¢Not Applicable.
‚Ä¢Unknown
The outcome of the AE: 
‚Ä¢Recovered/Resolved
‚Ä¢Recovering/Resolving
‚Ä¢Not Recovered/Not Resolved
‚Ä¢Recovered/Resolved with Sequelae
‚Ä¢Fatal
‚Ä¢Unknown
The causal relat ionship of the AE to the s tudy treatment: 
‚Ä¢Not related
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 58 13 October 2017 oNot related  - Improbable temporal relationship and is plausibly related to
other drugs or underlying disease.
‚Ä¢Related
oPossible  - occurred in a reasonable time after study drug administration, but
could be related to concurrent drugs or underlying disease.
oProbable  - occurred in a reasonable time after study drug administration, is
unlikely to be attributable to concurrent drugs or underlying disease, and there
is a plausible mechanism to implicate the study drug.
oDefinite  - occurred in a reasonable time after study drug administration and
cannot be explained by concurrent drugs or underlying disease. The adverseevent should respond to dechallenge/rechallenge, however, this is not
mandatory before assigning a definite causality.
The Medical Monitor is the initial contact person for protocol related questions or discussion of 
AEs. The contact information for the Medical Monitor as well as other emergency contact 
information can be found in Table 1 of this protocol. 
12.4. Immediately Reportable Events  
The following medical events must be immediately reported to  the Sponsor: 
‚Ä¢SAE
‚Ä¢Pregnancy
Emergency contact information can be found in T able 1. 
12.4.1. Serious Adverse Event  
If the Investigator or study center  staff becomes aware of a SAE that occurs in a study subject 
after first administration of study drug through 30 days following the last dose of the s tudy drug, 
this must be reported immediately to  the Sponsor whether considered related or unrelated to the 
study drug. SAEs must be recorded on the CRF and the data recorded should agree with that on 
the SAE form.  
Following the end of subject participation in the s tudy, the Investigator or an authorized delegate 
should report SAEs ‚Äúspontaneously‚Äù to PPD -PVG if considered at least possibly related to the 
study drug.  
SAEs will be followed until resolution, loss to follow-up, stabilization of condition, or the event is otherwise explained.  
In additi on to the initial telephone notification, a n initial SAE form as applicable must be 
completed and signed and sent via fax or email  (see Table 1 ) to PPD -PVG within 24 hours of the 
Investigator or s tudy center staff b ecoming aware of the event.  The SAE form must be signed by 
the Investigator or appropriate designee. PPD -PVG provides the SAE form used to report SAEs. 
The Sponsor or designee will promptly notify all study centers and Investigators of a SAE that is 
determ ined to be expedited to the Regulatory Authorities in accordance with  applicable law (s) 
and regulation(s ). These SAEs must be promptly reported to the Institutional Review Board 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 59 13 October 2017 (IRB) or Independent Ethics Committee (IEC) by the Investigator or the appropr iate person at 
the study center if required per IRB/IEC guidelines . 
For the UK, the appropriate Pharmacovigilance (PVG) group must be contacted immediately 
upon first knowledge of the incident. The immediate report should be made by the Investigator within  a very short period of time and under no circumstances should this exceed 24 hours 
following knowledge of the serious adverse event or pregnancy. 
12.4.2. Pregnancy  
Pregnancies  that occur from the time th at informed consent is signed through 90 days following 
the last dose of the s tudy drug will be collected and reported on the Pregnancy Event Form. 
If a subject  becomes pregnant during the course of the study, she will be instructed to commence 
discontinuation of the study drug. Further, t he subject (or female partner of male subject) will be 
instructed to return promptly/within 48 hours of the first notification of pregnancy to the study 
center  and undergo a serum/urine pregnancy test, as confirmation of pregnancy. If positive, the 
female pregnant subject will no longer receive any additional study drug . All pregnancies, 
whether or not the subject received any additional study drug , will be followed until resolution 
(ie, termination [voluntary or spontaneous] or birth). 
To report a pregnancy, the Pregnancy Event Form must be completed and sent via fax to 
PPD-PVG within  24 hours of the Investigator or s tudy center staff becoming aware of the 
pregnancy. The Sponsor provides the Pregnancy Event Form. If the subject received blinded study drug, unblinding of the study dr ug will be offered to the 
subject when knowledge of such treatment may have an impact on further treatment decisions. 
Otherwise, information regarding to what treatment the subject was assigned may be provided 
when the study has ended. 
Pregnancy itself is not regarded as an AE unless there is a suspicion that the study drug may have 
interfered with the effectiveness of a contraceptive medication  or other AEs were detected . 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 60 13 October 2017 13. TERMINATION OF SUBJECT FROM
STUDY/DISCONTINUATION OF STUDY DRUG
13.1. Criteria for Subject Termination/Study Drug Discontinuation  
Subjects may be discontinued from the study drug at any time for any of the following reasons: 
‚Ä¢Adverse event  (specify)
‚Ä¢Lack of efficacy (specify)
‚Ä¢Withdrawal by subject (specify)
‚Ä¢Non-compliance with study drug (specify )
‚Ä¢Protocol deviation (specify)
‚Ä¢Death
‚Ä¢Progressive disease
‚Ä¢Pregnancy
‚Ä¢Other (specify)
If at any time during the course of the study, in the opinion of the Investigator, the subject may 
no longer safely participate due to a change in medical status (eg, experiences an AE, becomes 
pregnant), the subject must be discontinued from the study drug. Subjects discontinued from 
study drug will be discontinued from the study. 
The reason and information on the epoch for study drug discontinuation will be recorded on the 
appropriate CRF. In case of death, the date of death should be captured on the CRF. 
13.2. Clinical Assessments after Study Drug Discontinuation  
Subjects who have not received study drug will not be followed up on leaving the study. For subjects who have received  study drug and prematurely discontinue from the study treatment 
(i.e., do not complete through Visit 11E), every effort should be made to complete the final 
evaluation procedures, in accordance with the early termination (ET) visit described in 
Section  11.6.9. 
All subjects who discontinue from the study early will complete a follow up visit 7  (¬±2) days 
after th e last visit to assess any post  study discontinuation adverse effects as described in  
Section  11.6.10. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 61 13 October 2017 14. STUDY TERMINATION
The Sponsor reserves the right to discontinue the s tudy at this study center or at multiple centers  
for safety  or administrative reasons at any time  while safeguarding that early termination doe s 
not compromise subjects‚Äô safety or well- being . In particular, a study center that does not recruit 
at an acceptable rate may be closed . Should the study be terminated and/or the study center 
closed for whatever  reason, all documentation and study drugs pertaining to the study must be 
returned to the Sponsor or its representative.  
If, in the opinion of the Investigator, clinical observations suggest it may be unsafe to continue, 
the Investigator may terminate part or the entire study after consultation with the Sponsor. 
In the event of s tudy or site termination, subjects will undergo final evaluation procedures, in 
accordance with the early termination (ET) visit described in Section  11.6.9 and safety follow-up 
visit as described in Section  11.6.10. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 62 13 October 2017 15. STATISTICS
15.1. Sample Size 
All subjects who complete the 4 -week double- blind treatment period of Study SEP361-201 are 
eligible. It is anticipated that approximately 180  subjects will enter this open -label extension 
study.  
15.2. Analysis Population  
15.2.1. Safety Population 
The safety population will consist of all subjects who receive at least one dose of study drug 
during the 26- week  open-l abel extension  period. The safety population will be used for the 
long- term safety, tolerability, and efficacy analyses . 
15.3. Data Analysis 
15.3.1. Subject Disposition  
Subject  disposition will be summarized and presented for the num ber and percentage of subjects , 
who entered the extension study , received at least one dose of the extension study treatment, and 
completed or discontinued the study (including reasons for discontinuation).  
15.3.2. Drug Exposure and Compliance  
Drug exposure and compliance during the open- label extension  period will be summarized for 
the safety population.  
Exposure (in days) wil l be calculated as: last extension study dose date - first extension study 
dose date + 1. Exposure will be summarized both as a continuous variable (i.e. mean days) and 
categorically :  
‚Ä¢Number and percentage of subjects with extens ion study drug exposure ‚â• 1, ‚â• 7, ‚â• 14,
‚â• 28, ‚â• 56, ‚â• 84, ‚â• 112, ‚â• 140, ‚â• 168, and ‚â• 182 days ;
‚Ä¢Number and percentage of subjects with extension study drug exposure for 1 - 6,
7 - 13, 14 - 27, 28 - 55, 56  - 83, 84 - 111, 112 - 139, 140 - 167, 168 - 181, and
‚â• 182 days
Percent com pliance will be calculated as: (number of capsules  taken / number of capsules  should 
have been taken ) √ó 100%. Percent compliance will be calculated by visit and overall for the 
entire open -label extension period, and will be summarized both as a continuous variable (ie,  
mean percentage)  and categorically (i.e. number and percentage of subjects in each compliance 
category: non-compliant < 75%, 75% - 125%, non- compliant > 125%, and missing compliance). 
Mean  daily dose will be calculated for the entire open -label extension period as the cumulative 
dose (mg) of SEP -363856 divided by the duration of exposure (in days), where cumulative dose 
is the sum of all doses a subject received during the open- label extension period. Modal daily 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 63 13 October 2017 dose will be determined as the daily dose that is taken for the most time (in terms of number of 
days)  among all doses taken . Both mean  daily dose and modal daily dose will be summarized.  
15.3.3. Important Protocol Deviations 
Important protocol deviations (IPDs) will be identified and documented based on a review of 
potentially IPDs. The potentially IPDs will be identified through programmatic checks of s tudy 
data, as well as through review of selected data listings. The potentially IPDs to be reviewed 
include, but are not limited to, subjects who: 
‚Ä¢Did not meet inclusion/exclusion criteria  for the open-label extension study.
‚Ä¢Received any disallowed concomitant medication  during the open- label extension
period.
Individual IPDs will be presented in a data listing. The number and percentage of subjects with 
IPDs will be summarized for the safety population by the type of deviation. 
15.3.4. Demographic and Baseline Characteristics  
Demographic and baseline characteristics data will be summarized for the safety population. 
Selected data (e.g. PANSS total scor e, CGI -S score, etc. ) will be summarized  at both the 
double-blind ( DB) baseline of study SEP361-201 and the open- label (OL) baseline of 
study SEP 361-202. 
Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA)  
version 18.1 or higher, and will be summarized for the safety population by presenting the 
number and percentage of subjects with at least one condition in each system organ class  (SOC) 
and preferred term  (PT). 
15.3.5. Efficacy Analyses 
Efficacy data will be summarized descriptively for the safety population. 
The absolute values of PANSS total score and subscale scores (positive, negative, and general 
psychopathology), CGI-S score, BNSS total score, and MADRS total score at both the DB baseline of study SEP361-201 and OL baseline of study SEP361-202, and at each scheduled 
post-baseline extension visit, wi ll be summarized descriptively.  
Changes from baseline in the above efficacy measures will be summarized at each scheduled 
post-baseline extension visit, based on both the DB baseline of study SEP361-201 and the OL 
baseline of study SEP361-202. 
PANSS total score and CGI -S score data will also be separately summarized by age group, 
gender, race, and geographic region (i.e. US sites vs. non-US sites). Additional subgroup factor s 
and details of the subgroup analysis will be provided in SAP. The proportion of subjects who achieve a response, defined as a 20% or greater improvement (i.e. 
decrease) in PANSS total score from the baseline at the end of the 26 -week open -label extension  
period, will be calculated based on: (1) the DB baseline of study SEP361-201 for subjects assigned to double-blind SEP-363856, and (2) the OL baseline of study SEP361-202 for subjects 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 64 13 October 2017 assigned to double-blind placebo. For subjects who discontinue early, t he PANSS total score 
measured at the early termination visit will be used.  
The CBB composite score at the DB baseline of study SEP361-201 and OL baseline of study 
SEP361-202 will be calculated. The composite score based on the four domains contained in the CBB scale (i.e. attention, information processing, visual learning, and working memory) will be 
calculated from the CSB assessment result at Visit 7E (Week  12) and Visit 11E (Week  26) of 
study SE P361-202. The composite score of CSB at Visits 7E and 11E wi ll also be calculated.  
The absolute values of CBB composite score at the DB baseline of study SEP361-201 and the OL baseline of study SEP361-202, and the four- domain composite score at each scheduled 
post- baseline extension visit, will be summarized descr iptively. Changes from baseline in 
four-domain composite score will be summarized at each scheduled post- baseline extension visit, 
based on both the DB baseline of study SEP361-201 and the OL baseline of study SEP361-202. 
In addition, the absolute values of CSB composite score at Visits  7E and 11E of study 
SEP361-202 will be summarized. Change from Visit 7E in CSB composite score at Visit 11E 
will also be summarized.  
The absolute values of UPSA- B total score at the OL baseline of study SEP361 -202, and at ea ch 
scheduled post- baseline extension visit, will be summarized descriptively. Changes from the OL 
baseline in UPSA -B total score will be summarized at each scheduled post -baseline extension 
visit.  
15.3.6. Safety Analyses 
15.3.6.1. Adverse Events  
All AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA)  
version 18.1 or hi gher. AEs are untoward medical occurrences: 
‚Ä¢that occurred on or after the first dose of study drug,
‚Ä¢with a missing start date and a stop date on or after the first dose of study drug, or
‚Ä¢with both a missing start and stop date.
For the present  study the summary of AEs will be limited to those tha t occurred on or after the 
first dose (of the 26-week open- label extension period) of the study drug. 
AEs will be summarized by MedDRA system o rgan class  (SOC) and Preferred Term (PT).  
The following AEs wil l be summarized and presented by MedDRA SOC and PT for the Safety  
population: 
‚Ä¢All AEs (including number of events and subject incidence).
‚Ä¢AEs by severity (mild, moderate, severe).
‚Ä¢AEs by relati onship to the study treatment (related, or not related).
The following conventions will be followed in summarizing AEs: 
‚Ä¢For subject incidence summaries, each subject will be counted only once within eachSOC and within each preferred term.
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 65 13 October 2017 ‚Ä¢If a subject rep orts more than one AE within a preferred term and/or a body system,
the AE with the highest known severity within each body system and within each
preferred term will be include d in the summaries by severity.
‚Ä¢For summaries by relationship to the study drug , AEs will be grouped as ‚Äúrelated‚Äù or
‚Äúnot related.‚Äù AEs assessed as ‚Äúpossible,‚Äù ‚Äúprobable,‚Äù or ‚Äúdefinite,‚Äù will be grouped
as ‚Äúrelated.‚Äù If a subject reports more than one AE within the same treatment
regimen, SOC and PT, and any are related, it will be s ummarized as related.
Summaries of SAEs and AEs leading to discontinuation will also be provided. A listing of AEs, 
as well as a listing of death s, SAEs , or AEs leading to discontinuation, will be presented. 
15.3.6.2. Clinical Laboratory Assessments 
Clinical laboratory parameters will be summarized by presenting shift tables, and by presenting summary statistics for the absolute values as well as the change from Baseline values. Both the 
DB baseline of study SEP361-201 and the OL baseline of study SEP361- 202 will be  used  in the 
calculation  of change values . For laboratory parameters with categorical outcomes, the number 
and percentage of subjects with each outcome will be presented. The data listings will flag values 
outside the reference range.  
15.3.6.3. ECGs 
Absolute values and changes from Baseline in ECG parameters will be summarized. In addition, 
the number and percentage of subjects with elevated QTc intervals (> 450 msec, > 480 msec, and 
> 500 msec) and changes from baseline in QTc intervals ‚â• 30 msec and ‚â• 60 msec will be 
summarized. Fridericia‚Äôs correction (QTcF) and Bazett‚Äôs correction (QTcB) will be used for QT interval correction.  Both the DB baseline of study SEP361-201 and the OL baseline of study 
SEP361-202 will be used in the calculat ion of change values. 
15.3.6.4. Vital Signs  
Vital sign parameters, as well as weight and BMI, will be summarized by presenting summary statistics for the absolute values and the change from Baseline values.  Both the DB baseline of 
study SEP 361-201 and the OL baselin e of study SEP 361-202 will be used in the calculation of 
change values.  
15.3.6.5. Physical/Neurological Examination 
All physical and neurological exam findings at  the screening visit of study SEP361-201 will be 
recorded as medical history events.  Clinically signific ant findings at the extension visits will be 
captured as AEs as appropriate and summariz ed together with the other AEs.  
15.3.6.6. Concomitant Medications  
All medications will be coded to indication -specific ATC (Anatomical Therapeutic Chemical) 
classification (i.e.  ATC level  3) and preferred name using the World Health Organization Drug 
Dictionary (WHO -DD).  
Any medications taken during the course of the open -label extension study, with a start date on 
or after the date of the first dose of extension study drug and on or before the date of the last dose 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 66 13 October 2017 of extension study drug; or with a start date prior to, and an end date on or after, the date of the 
first dose of extension study drug, or marked as ongoing, will be considered concomitant 
medications. Medications tha t ended prior to the date of the first dose of extension study drug 
will be considered prior medications. Medications that started after the date of the last dose of 
study drug will not be considered concomitant, but will be considered post- treatment. Prio r and 
Concomitant medications will be summarized for the number and percentage of subjects using each medication and by the drug class and preferred name for the safet y population. 
15.3.6.7. Suicidality Measure  
Frequency and severity of suicidal ideation and suicida l behavior as measured by the C-SSRS 
scale will be summarized for each visit.  
15.3.6.8. Rate of Relapse and Time to Relapse 
The relapse will be assessed in subjects who demonstrated clinical response to 4  weeks of 
treatment with SEP -363856. Clinical response is defined as meeting both of the following 
criteria : 
1) a decrease in PANSS total score of ‚â• 20% from baseline, and2)a CGI -S score ‚â§ 4.
For subjects assigned to double-blind SEP -363856, clinical response will be evaluated using the 
Day 29 data of study SEP361-201, against the DB baseline of study SEP361-201. For subjects 
assigned to double-blind placebo, clinical response will be evaluated using the Day 29 data of 
study SEP 361-202, against the OL baseline of study SEP361-202. 
Relapse will be identified programmatically using the pre- defined criteria ( Section  6.2) among 
subjects who demonstrated a clinical response to 4 weeks of treatment with SEP -363856. The 
rate of relapse will be calculated as the proportion of subjects wi th a relapse in the 26- week 
open-label extension period out of all subjects who demonstrated clinical response, along with 
the 95% confidence interval. The time- to-relapse will be summarized descriptively and will also 
be presented by a Kaplan -Meier plot . 
15.3.6.9. Movement Disorder Measures  
Movement disorder measures include AIMS, BARS, and SAS . The absolute values of AIMS, 
BARS, and SAS  total scores at both the DB baseline of study SEP361-201 and OL baseline of 
study SEP 361-202, and at each scheduled post- baseline extension visit, will be summarized for 
the safety population. Changes from baseline in these measures will also be summarized for each scheduled post-baseline extension visit, using both the DB baseline of study SEP361-201 and OL 
baseline of study SEP361- 202 to calculate the change values.  
15.3.6.10. Drug Effects Questionnaire  
Data from the DEQ questionnaire will be summarized for the safety population at each visit. 
15.3.6.11. Pittsburgh Sleep Quality Index  
Absolute PSQI global score at both the DB baseline of study SEP361-201 and OL baseline of 
study SEP 361-202, and at each scheduled post- baseline extension visit, will be summarized for 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 67 13 October 2017 the safety population. Change from baseline in PSQI global score will also be summarized for 
each scheduled post -baseline extension visit, based on both the DB baseline of study 
SEP361-201 and the OL baseline of study SEP361-202. 
15.3.6.12. Subgroup Analysis  
Selected safety data will be presented by age group, gender, race, and geographic region/country. 
Additional subgroup factors and details of subgroup analysis of the safety data will be provided 
in the SAP.  
15.3.7. Pharmacokinetic Analysis 
All concentrations will be presented in data listings. POP PK analysis will be performed using 
plasma SEP -363856 concentrations; the results of which will be reported separat ely. 
15.3.8. Pharmacodynamic Analysis 
The relationship between PANSS total score and plasma SEP -363856 exposure using population 
PK/pharmacodynamics (PD) methods will be explored, the results of which will be reported separately.  
15.3.9. Interim Analysis  
No interim analys is is planned. 
15.3.10. Treatment of Missing Data  
For rating scales with more than one item, such as PANSS and MADRS, if any item score contributing to the total/subscale score is missing, then the total/subscale score will be set to 
missing.  
In this study , missing  data will not be imputed. All analyses will be based on the observed data.  
15.3.11. Sensitivity Analyses 
No sensitivity analysis will be performed.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 68 13 October 2017 16. PROCEDURE FOR CLINICAL STUDY QUALITY CONTROL
/DATA COLLECTION, MANAGEMENT, AND QUALITY
ASSURANCE
16.1. Data Collection/ Electronic Data Capture (EDC)  
The results from data collected during the study (except clinical laboratory test results)  will be 
recorded in the subject‚Äôs  electronic CRF.  Data will be entered into source documents prior to 
being transcribed into the CRF. This transcribing will be done once a subject has been enrolled at  
baseline (Visit 1E) . Data for screen failures will not be collected. The study centers will use an 
EDC system that is compliant with relevant FDA regulatory requirements per  21 code of federal 
regulations (CFR) Part  11. Password protected access to the EDC system will be via a secure 
website. Data queries and data corrections will be handled through the same system. All 
transactions within the EDC system are fully documented within an electronic  audit trail. Each 
set of completed CRFs must be reviewed and electronically signed and dated by the Investigator 
or delegate.  
16.2. Computerized Systems Used for Source Data  
A list of the computerized systems that will be used to create, modify, maintain, archive, retrieve, or transmit source data are presented below, pursuant to the Guidance for Industry Computerized Systems Used in Clinical Investigations, May  2007. 
Protocol Step Computerized System Type or 
Description  
Obtain informed consent  A 
Review inclu sion/exclusion criteria  A 
Demographics  A 
Prior/concomitant medication review  A 
Dispense study drug  A, E 
Study drug accountability  A 
Physical examination  A 
Vital sign measurements  A 
Weight  A 
Waist circumference  A 
Electrocardiogram (ECG)  C 
Hematolo gy, chemistry, and urinalysis B 
Serum prolactin  B 
Glycosylated hemoglobin (HbA 1c) B 
Glucose and Lipid panel  B 
Serum human chorionic gonadotropin (Œ≤ -hCG)  B 
Blood sample for SEP-363856 PK  D 
Urine drug screen  B 
Urine Œ≤ -hCG  (local)  A 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 69 13 October 2017 Protocol Step Computerized System Type or 
Description  
Urine drug scree n (central)  B 
Positive and Negative Syndrome Scale (PANSS) ‚Äì Total 
Score  F 
Clinical Global Impression ‚Äì Severity (CGI -S) F 
Montgomery -Asberg Depression Rating Scale (MADRS)  F 
Columbia Suicide Severity Rating Scale (C -SSRS) F 
Drug Effects Questionnair e (DEQ)  A 
Abnormal Involuntary Movement Scale (AIMS)  F 
Barnes Akathisia Rating Scale (BARS)  F 
Simpson -Angus Scale ( SAS) F 
Brief Negative Symptoms Scale ( BNSS ) F 
Pittsburg Sleep Quality Index (PSQI)  F 
CogState Brief Battery (CBB)  G 
CogState Schizophr enia Battery (CSB)  G 
USPA -B A 
Adverse events (AE) monitoring  A 
Statistical analysis  SAS¬Æ, version  9.2 or higher  
A = EDC (MediData RAVE); B  = L IMS; C  = Core Lab Over -read; D  = LIMS/ASCII; E  = IXRS  F = Bracket ; 
G = CogState .  
Abbreviations: EDC  = elect ronic data capture; CDR  = clinical data repository; CIMS = Clinical Inventory 
Management System; IXRS  = interactive response technology; IVRS  = interactive voice recognition system; 
LIMS  = laboratory information management system.  
16.3. Study Monitoring  
This study will be monitored from initiation to completion  by the Sponsor or its representative. 
Monitoring will include personal visits and telephone communication to assure that the 
investigation is conducted according to protocol and in order to comply with ICH GCP. On -site 
review of CRFs will include a review of  forms for completeness and clarity, and consistency 
with source documents available for each  subject. 
16.4. Audits 
The study may be subject to audit by the Sponsor/designee. If such an audit occurs, the 
Inves tigator must agree to allow access to  required subject records. This is dependent on the 
subject granting consent by signing the ICF. By signing this protocol, the Investigator grants permission to personnel from the Sponsor or its representatives for on -site monitoring and 
auditing of all appropriate study documentation, as well as on- site review of the  procedures 
employed in CRF generation, where clinically appropriate. 
In accordance with ICH GCP the Sponsor may select this study for audit. During the audit the 
Sponsor representative will carry out an inspection of centre facilities (eg,  pharmacy, drug 
storage areas, laboratory) and review study related records in order to evaluate the study 
compliance with the Sponsor/centre SOPs, protocol, ICH GCP and local regulations. The 
Investigator or appropriate designee must also agree to inspection of all study documents by the 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 70 13 October 2017 regulatory authorities and the IEC. Should the I nvestigator  or appropriate designee be notified of 
a regulatory inspection involving this study they should notify the Sponsor immediately. 
16.5. Study Documentation  
Study records are comprised of source documents, CRFs, and all other administrative 
documents, eg, IRB/IEC correspondence, clinical study materials and supplies shipment 
manifests, monitoring logs, Sponsor and CRO correspondence, etc. A s tudy specific binder will 
be provided with instructions for the maintenance of study records. 
Source document is defined as any hand written or computer generated document that contains 
medical informatio n or test results that have been collected for or are  in support of the protocol 
specifications, eg, clinical lab oratory reports, clinic notes, drug disbursement log, subject sign in 
sheets, subject completed questionnaires if applicable , telephone logs, ECGs, etc. All draft, 
preliminary and pre-final iterations of a final report are also considered to be source documents, 
eg, faxed lab oratory reports and hard copy laboratory reports, faxed initial results and hard copy, 
final report.  
16.6. Clinical Laboratory Ce rtification and Normal Values  
A central laboratory will be used for analysis for most of the clinical laboratory tests for this 
study. The central laboratory will provide the Investigator, Sponsor/CRO with laboratory certification(s), a dated copy of norma l range values for the central clinical laboratory selected to 
analyze clinical specimens. If an exception is granted to use a local laboratory, the Investigator 
must supply the Sponsor/CRO with laboratory certification, lab director‚Äôs c urricula vitae  and a 
current, dated copy of normal range values.  
A local laboratory may optionally be used for analysis of serum pregnancy at Visit 2 in this study. The local laboratory/site personnel will provide Sponsor/P1vital with laboratory 
certification(s) and a current dated copy of normal range values for the local clinical laboratory 
selected to analyse clinical specimens.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 71 13 October 2017 17. ETHICAL AND REGULATO RY OBLIGATIONS
17.1. Study Conduct  
The Investigator agrees that the study will be conducted according to the protocol, ICH Good 
Clinical Practice (GCP) , ICH guidelines  and the ethical principles that have their origin in the 
Declaration of Helsinki. The Investigator will conduct all aspects of the study in accordance with 
applicable local law(s) and regulation(s ). 
The Investigator will assure proper implementation and conduct of the study including those 
study-related duties delegated to other appropriately qualified individuals. The Investigator will 
assure that study staff cooperate with monitoring and audits. 
The Investigator must sign and return to Sponsor/ CRO the ‚ÄúInvestigator Approval " page . 
17.2. Institutional Review Board /Independent Ethics Committee  
Documented approval for conducting the study from appropriate Institutional Review Board (IRB)/ Independent Ethics Committee ( IEC) will be  obtained for all participating study centers  
prior to initiation of the study, according to ICH GCP, applicable local law(s) and regulation(s). 
When necessary, an extension, amendment or renewal of the IRB/ IEC approval must be obtained 
and also forwarded to the Sponsor. The IRB/IEC must supply the Sponsor a list of the IRB/I EC 
membership, and a statement to confirm that the IRB/ IEC is organized and operates according to 
ICH GCP, applicable law(s) and regulation(s). 
A copy of written IRB/ IEC a pproval or favorable opinion of the protocol, informed consent form 
and subject recruitment material (if applicable) must be provided to Sponsor/CRO prior to start 
of the s tudy.  The approval or favorable opinion letter must be signed by the IRB/ IEC chairman 
or designee identify the IRB/IEC name and address, identify the clinical protocol by title and/or 
protocol number, and include the date that approval or favorable opinion was granted. The letter must also contain a statement that the IRB /IEC complies with the requirem ents in 21 CFR 
Part 56 for a s tudy conducted under a US investigation new drug ( IND) or ICH GCP, as 
applicable.  
The Investigator/CRO is responsible for obtaining from the IRB/IEC continued review of the 
clinical research or submitting periodic progress rep orts, in accordance with applicable 
regulations, at intervals not to exceed one year and (if applicable) as otherwise additionally 
specified by the IRB/ IEC. The Sponsor must be supplied with written documentation of 
continued review of the clinical research. 
The Investigator must promptly inform their IRB/IEC  of all SAEs reported by subjects enrolled 
in the study or other safety information reported from Sponsor/CRO in accordance with 
applicable law (s) and regulation(s). 
17.3. Informed Consent  
The informed consent form will be approved by the Sponsor/CRO prior to submission to the 
IRB/IEC. All informed consent forms must contain the minimum elements as mandated by ICH 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 72 13 October 2017 GCP, applicable local law(s) and regulations and will be subject to Sponsor /CRO  approval as 
well as IRB /IEC approval. 
Before recruitment and enrollment, each prospective subject will be given a full explanation of 
the study, allowed to read the approved informed consent form and be provided ample time and 
the opportunity to ask any questions that may arise. Once all questions have been answered and 
the Investigator is assured that the prospective subject understands the implications of 
participating in the study, the prospective subject will be asked to give consent to participate in 
the study by signi ng the informed consent form. As part of the consent process, each prospective 
subject must consent to direct access to his/her medical records for study-related monitoring, 
auditing, IRB/IEC review, and regulatory inspection. It should be clearly explaine d to each 
prospective subject that participation in each and every clinical visit and assessment is expected.  
The subject may be discontinued from study drug, but that does not necessarily negate the expectation that the subject will continue to participate in the study through the final visit/assessment.  The Investigator will provide a copy of the signed informed consent form to 
each subject , and will record the date of the informed consent on the CRF. 
If an amendment to the protocol changes the subject participation schedule in scope or activity, or if important new information becomes available that may be relevant to the subject‚Äôs consent, 
the informed consent form must be revised, submitted to the IRB/IEC for review and approval or favorable opinion. The revised informed consent form must be used to obtain consent from a subject currently enrolled in the s tudy if he or she is affected by the amendment. The revised 
informed consent form must be used to obtain consent from any new subjects who are enrolled into the study after the date of the approval or favorable opinion of the protocol amendment.  
17.4. Subject Privacy 
The Sponsor (or Sponsor representative) or any designees affirm uphold the subjects 
confidentiality.  The subject will be identified by unique code only; full names will be masked 
prior to transmission to the Sponsor. The confidentiality of the subject‚Äôs personal data shall be 
protected in accordance with appropriate laws and regulations. 
If any cases are identified where the subject‚Äôs confidentiali ty has been breached, this must be 
rectified immediately. All subject identifiable information should be removed and the Sponsor notified. 
17.5. Protocol Amendments and Emergency Deviations 
All revisions and/or amendments to this protocol must be approved in writing by the Sponsor 
and the appropriate IRB/IEC. The Investigator will not make any changes to the conduct of the 
study or the protocol without first obtaining written approval from the Sponsor and the IRB/IEC, except where necessary to eliminate an apparent immediate hazard to a study subject.  
Emergency deviations or modifications may be initiated without Sponsor or IRB/IEC approval or favorable opinion, only in cases where the deviation or modification is necessary to eliminate or avoid an immediate apparent hazard to subjects. Emergency deviations or modifications must be 
reported to the Sponsor/CRO and the IRB/IEC  immediately/within five  business days of the 
occurrence, or in accordance with applicable regulatory requirements. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 73 13 October 2017 17.6. Records Retention  
The Inves tigator /the study center must arrange for retention of s tudy records at the study center  
for at least 25 years from time of participation in the study or longer in accordance with 
applicable regulations and Sponsor SOPs. The Investigator /site should take m easures to  prevent 
accidental or premature destruction of these documents. Documents cannot be destroyed  without 
written Sponsor authorization. The Sponsor will inform the Investigator/ the study center  when 
the destruction of documents is permitted. 
17.7. Inspection of Records  
In the event of an inspection, the Investigator agrees to allow representatives of the Sponsor and  
its representative and , the regulatory authorities‚Äô access to all study records . The Investigator will 
promptly notify the Sponsor /CRO of all  requests to inspect a Sunovion-sponsored study by 
government agencies and will promptly forward a copy of all such inspection reports. 
17.8. Publication Policy  
Any formal presentation or publication of data collected as a direct or indirect result of the study 
will be considered a joint publication by the Investigators and the appropriate personnel of the 
Sponsor . For multicenter studies, it is mandatory that the first publication is based on all data 
obtained from all analyses as stipulated in the protocol. Inv estigators participating in  multicenter 
studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other Investigators and by the 
Sponsor. 
The Sponsor will disclose the study results, in the form of a clinical study report synopsis, to the 
IEC and the applicable regulatory authorities within one year of the end of the study. The format 
of this synopsis and that of the clinical study report should comply with ICH E3 guidelines for structure and content of a clinical study report. 
Investigators participating in  multicenter studies must agree not to present data gathered 
individually or by a subgroup of centers before the full, initial publication, unless this has been 
agreed to by all other Investigators  and by the Sponsor. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 74 13 October 2017 18. REFERENCES
American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental 
Disorders.  4th ed; 2000. 
Ascher -Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of 
relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry.  2010;10:2-7. 
Barnes TRE. A rating scale for drug -induced akathisia. Br J Psychiatry 1989;154:672-676.  
Barnes TRE. The Barnes Akathisia Rating Scale ‚Äì Revisited. J Psychopharmacology 2003; 
17(4): 365-370. 
Buysse, Daniel J.; Reynolds, Charles F.; Monk, Timothy H.; Berman, Susan R.; Kupfer, David J. 
(May 1989). "The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research". Psychiatry Research 28 (2): 193‚Äì213. .doi:10.1016/0165-1781(89)90047-4 
Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin 
Psychopharmacology. 2004;24:192-208. 
Guy W. EDCEU Assessment Manual for Psychopharmacology ‚Äì Revised ( DHEW Publ No 
ADM 76 -338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public 
Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH 
Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:534-
537. 
Kay SR, Opler LA, Fisbein A. Positive and Negative Syndrome Scale Manual. North 
Tonawanda, NY: Multi-Health Systems, 1994. 
Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the 
treatment of schizophrenia. Annu R ev Med  2001;52:503-517. 
Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline 
neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 
2006;31:2033-2046. 
Kim DH, Maneen MJ, Stahl SM. Building a better anti psychotic: receptor targets for the 
treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6:78-85. Kirkpatrick B, Strauss GP, Nguyen L, et al. The Brief Negative Symptom Scale: Psychometric 
Properties. Schizophrenia Bulletin. 2011;37(2):300-305. doi:10.1093/schbul/sbq059. 
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes 
Research Team (PORT): updated treatment recommendations  2009. Schizophr Bull. 
2010;36:94-103. 
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: 
a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199-212. 
Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with 
schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 75 13 October 2017 Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-
generation antipsychotic drugs for schizophrenia: a meta- analysis. Lancet.  2009;373:31-41. 
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl  J 
Med.  2005;353:1209-1223. 
Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL. Development of a brief scal e 
of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33:1364‚Äì1372.  
Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Philips D, Xu, J, Kalali, AH, Schweizer E, Pikalov 
A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo -and olanzapine-controlled study. Am J Psychiatry.  2011;168:957-967. 
Minzenberg, et al. Chapter 10: Schizophrenia. In: Hales RE, Yudofsky SC, Gabbard GO, eds. The American Psychiatric Publishing Textbook of Psychiatry. 5th edition. Arlington, VA: American Psychiatric Publishing, Inc; 2008. 
Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and 
rehospitalization in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32-37. 
Munetz MR, Benjamin S. How to examine subjects using the Abnormal Involuntary Movement 
Scale. Hospital and Community Psychiatry 1988; 39: 1172-1177. 
Munro J, Osborne S, Dearden L, Pascoe K, Gauthier A, Price M. Hospital treatment and 
management in relapse of schizophrenia in the UK: associated costs. The Psychiatrist. 
2011;35:95-100. 
Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and 
implications for clinicians. CNS  Drugs. 2009;23:649-659. 
Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829-836. 
Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders 
in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002;59:115-123. 
National Institute of Mental Health (NIMH). Schizophrenia. 
http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booket-2009.pdf. Accessed October 20, 2010. 
Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 
2007;68 (suppl 4):8-13. 
Opler LA, Kay SSR, Lindenmayer JP, Fiszbein A. Structured Clinical Interview for the Positive 
and Negative Syndrome Scale (SCI -PANSS). Toronto: Multi-Health Systems, 1992. 
Patel KH, Hlavinka PF. Schizophrenia: Optimal therapy with second-generation antipsychotic 
agents. Pharmacy Today. 2007;13:71-84. 
Pearlson GD. Neurobiology of schizophrenia. Ann Neurol. 2000;48:556-566. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 76 13 October 2017 Perkins DO, Stroup TS, Lieberman JA. Psychotic disorders measures. In Handbook of 
Psychiatric Measures. Washington, D.C.: American Psychiatric Association, 2000 p. 485-513.  
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classif ication Algorithm of 
Suicide Assessment (C -CASA): classification of suicidal events in the FDA's pediatric suicidal 
risk analysis of antidepressants. Am J Psychiatry.2007 Jul; 164 (7):1035-1043. Schultz SK, Andreasen NC. Schizophrenia. Lancet. 1999;353:1425-1430. 
Siddiqui O, Hung HM, O'Neil R. MMRM versus LOCF: A comprehensive comparison based on 
simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics, 2009; 19: 227-
246. 
Simpson GM, Angus JWS. A rating scale for extrapyramidal side eff ects. Acta Psychiatrica 
Scandinavia, Suppl 1970; 212S: 11-19. 
Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry 
Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Res. 2008;100:20-38. 
Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold? 
Current Psychiatry Reports. 2008;10:352-358. 
Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the 
Montgomery-Asberg Depression Rating Scale (SIGMA). Br J Psych. 2008; 192: 52-58. 
Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed 
schiz ophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36:1535-1540. 
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 77 13 October 2017 19. INVESTIGATOR APPROVAL 
I have read the protocol,  SEP361-202, Version 4.00 ‚Äú A 26 -Week Open -label Safety and 
Tolerability Extension Study of SEP -363856 in Adult Subjects with Schizophrenia ‚Äù, and agree 
that it contains all necessary details for conducting the study and to conduct the s tudy in strict 
accordance with the specifications outlined herein.  
I agree that no additional procedure(s) will be added during the conduct of the study except 
through protocol amendment by Sunovion Pharmaceuticals Inc. and after documentation of IRB 
approval. 
Investigator Signature: ____________________________________________________ 
 
Print Investigator Name: __________________________________________________  
Date: ___________________________________________ 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 78 13 October 2017 20. APPENDIX I. CARDIAC SAFETY M ONITORING  (ECG) 
1. Requirements for Testing  
Electrocardiogram ( ECG ) equipment and supplies will be provided by the centralized cardiac 
safety v endor and should be used for all in -clinic protocol ECG assessments.  
‚Ä¢ All 12-lead ECGs will be recorded in the same manner.  
‚Ä¢ The study center  personnel must be adequately trained in performing ECGs on the 
specific ECG equipment used in this protocol that is provide d by the cardiac safety 
vendor. 
‚Ä¢ To the extent possible, the same ECG machine and personnel should be used to 
acquire a subject‚Äôs ECGs throughout the period of their participation in the s tudy.  
‚Ä¢ ECGs will be recorded with at least one 10 -second single- lead tracing record ed from 
Lead II.  
2. Subject Restrictions and Instructions  
‚Ä¢ Prior to ECG acquisition, the subject will have rested 10 minutes in the supine position and will remain so until the ECG is obtained. 
3. Reporting  
‚Ä¢ It is the responsibility of the Investigator to perform a safety review of the ECG data 
for changes from previous assessments and/or emergent cardiac dysfunction, and to determine subjects‚Äô eligibility or continuance in the study.  
‚Ä¢ ECGs will be reviewed, signed and dated by the Investigator listed on the Form 
FDA 1572 (MD or DO) after each ECG collection. The same Investigator should 
review all ECG reports for a given subject whenever possible. 
‚Ä¢ For all ECGs, a report will be provided by the cardiac safety vendor to the study 
center  for review and signature. 
‚Ä¢ The E CG tracing will be kept with subject‚Äôs source documentation and / or CRF 
unless it is specified otherwise. The original ECG and the cardiologist‚Äô s over -read 
will be retained at the study center . 
4. Data Standardization 
ECG data will be transmitted to a centra lized cardiac safety vendor and centrally over -read 
and interpreted using standardized procedures. 
 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 79 13 October 2017 21. APPENDIX II . HIGHLY EFFECTIVE CONTRACEPTIVE  
PROCEDURES  FOR AND DURING THE STUDY 
For female subjects  
Female subject of reproductive potential agrees to remai n abstinent or use highly effective 
and reliable contraception throughout the study and for at least 30 days after the last dose of 
study drug has been taken. In the Investigator's judgment, the subject will adhere to this 
requirement.  
a. Highly effective  contraception is defined as continuous use of either two barrier 
methods (eg, condom and spermicide or diaphragm with spermicide) or a hormonal 
contraceptive. Highly effective hormonal contraceptives include the following:  
i) contraceptive implant (such as Norplant¬Æ) implanted at least 90  days prior to 
screening;  
ii) injectable contraception (such as medroxyprogesterone acetate injection) given 
at least 14  days prior to screening; or  
iii)  oral contraception taken as directed for at least 30  days prior to screening. 
b. Subjects who are of non-reproductive potential, ie, subject who is surgically sterile, 
has undergone tubal ligation, or is postmenopausal (defined as at least 12 months of 
spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) concentrations within postmenopausal range as determined by laboratory analysis  based on study SEP361-201) are not required to 
remain abstinent or use highly effective contraception. 
For Male Subjects  
Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a 
child and use highly effective  methods of birth control from screening until at least 30 days 
after the last study drug administration . Male subjects must be surgically sterile or willin g to 
use an effective method of double-barrier birth control as outlined for female subjects above.  
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 80 13 October 2017 22. APPENDIX III. CLINICAL  LABORATORY TESTS 
Detailed instructions will be provided in a study center  manual.  
The following clinical laboratory tests are to be p erformed:  
 
Clinical Safety Panel  
 
HEMATOLOGY:  (Differential reported as % and absolute value)  
Hemoglobin, Hematocrit, Platelet Count, RBC Count, WBC - Total Count, WBC Differential, (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils) 
 
BLOOD CHEM ISTRIES : Alanine aminotransferase (ALT) , Albumin, Alkaline Phosphatase 
(ALP), Aspartate aminotransferase (AST), Bicarbonate (HCO 3), Bilirubin (Total, Direct, 
Indirect), Blood Urea Nitrogen (BUN), Calcium (Ca), Chloride (Cl), Creatinine, Creatine 
phosphokinase (CPK) , Glucose, Hemoglobin A1c (HbA 1c), Magnesium (Mg), Phosphorus (P), 
Potassium (K), Prolactin, Protein (Total), Sodium (Na), Uric Acid 
 
URINALYSIS:  Blood, Glucose, Ketones, Leukocyte esterase, Microscopic examination, 
Nitrites, pH, Protein  
 
LIPID PA NEL: LDL-Cholesterol, HDL -Cholesterol, Triglycerides 
 
THYROID PANEL:  Free T3, Free T4, Thyroid stimulating hormone (TSH) 
 
URINE DRUG SCREENING: Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids, 
Cocaine, Methamphetamines, Methadone, Methylenedioxym ethamphetamine (MDMA), 
Phencyclidine (PCP), Opiates, Oxycodone 
 
OTHER TESTS:  Serum Pregnancy ( Œ≤-HcG) (in female subjects only), Urine Pregnancy Te st 
(in female subjects only), Glycosylated hemoglobin (HbA 1c) 
 
Laboratory reports will be initialed and dated on all pages by the Investigator listed on the Form 
FDA  1572 (MD or DO). Laboratory test resul ts will be reviewed by the Investigator as they 
become available. The Investigator must determine the clinical significance of all out-of- range 
lab values (except drug screens). Possibly drug- related or clinically relevant abnormal values of 
uncertain caus ality must be repeated. Any abnormal values that persist should be followed at the 
discretion of the Investigator. 
Protocol S EP361-202, Version4.00 SEP-363856 
Confidential and Proprietary 81 13 October 2017 23. APPENDIX IV. PHARMACOKINETIC SAMPLING  AND 
SAMPLE  HANDLING  GUIDELINE   
 
Please refer to the Laboratory Investigator Manual for all collection a nd shipping instructions. 
 
When blood sample for PK assessment and clinical lab sample collections share the same 
designated time points (including predose sample), the blood samples should be collected during 
the same venipuncture. 
For each defined PK sa mpling time point, collect 6  mL blood sample into a K2- EDTA treated 
tube. Invert gently 8 to  10 times. Keep the blood collection tube on wet ice, and centrifuge for 
20 minutes at ca.  x 1300 g to isolate plasma within 30  minutes of blood draw. To ensure a m ore 
homogenous sample, all plasma samples should first be transferred to 1 tube, capped and mixed 
well. Split the harvest plasma sample with approximately equal volume into 2  polypropylene 
tubes, and label as Primary and Back -up. Freeze plasma tubes in a freezer at 
approximately -20¬∞C or lower. The date and clock time of blood collection must be recorded. 
Blood must be collected from all subjects at the time points indicated below.  
All samples will be shipped with sufficient dry ice protection.  
 
Study Day  Collection Time  Volume Collected  
Visit  2E ( Day 8) Post-dose (Actual date and time will be recorded) 6 mL  
Visit  5E ( Day 29) Post-dose (Actual date and time will be recorded) 6 mL  
Visit  8E ( Day 113) Post-dose (Actual date and time will be recorded) 6 mL  
Visit 11E ( Day 183) Post-dose (Actual date and time will be recorded) 6 mL  
 